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INFLUENCE OF BILBERRY-DERIVED ANTHOCYANIDINS ON KEY REGULATORS OF 
COLORECTAL CANCER DEVELOPMENT 




Colorectal cancer (CRC) is the third leading cause of cancer-related deaths within the United 
States.  A variety of factors including exposure to environmental carcinogens, such as 
benzo[a]pyrene (B[a]P),  dysbiosis of the gut microbiome and hereditary influences, including 
APC mutations, have been shown to lead  to an increased risk of developing colorectal 
cancer. Given the recent alarming rise in cases of colorectal cancer diagnosed in individuals 
under the age of 40, further insight into developing novel and effective prevention and 
treatment strategies are warranted. The family of plant pigments known as the anthocyanins 
has been identified with a variety of health benefits including chemopreventive and 
therapeutic effects. However, a limitation to current clinical applications of anthocyanins is 
the high doses that are required. In order to overcome this barrier we tested the active 
moiety, anthocyanidins, native bilberry mixture of anthocyanidins (Anthos), at various doses 
for chemopreventive and therapeutic effects against colorectal cancer both  in vitro and in 
vivo. Anthos treatment led to favorable modulation of several key contributors to the 
development of CRC including Src/EGFR pathway, Phase I/II enzyme expression and the 
inflammatory microenvironment, with special emphasis on the expression of PD-L1, a key 
immune checkpoint protein both in vitro  and in vivo using an Apc
Min/+ 
ETBF mouse tumor 
model. These results provide a promising outlook on the impact of berry Anthos for treatment 
and prevention of bacteria and B[a]P-driven colorectal cancer. Results from this study also 
vi 
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PREFACE, BACKGROUND & INTRODUCTION 
Preface 
Previously thought to have been a disease on the decline, colorectal cancer 
(CRC) has recently made a comeback in younger individuals. Of these cases of 
CRC, the majority are in the distal and rectal regions. The exact cause(s) for this 
alarming uptick have yet to be identified. Given this alarming rise, there is an 
urgent need for research in both the prevention and treatment of CRC. With this 
in mind, the focus of my doctoral research has been to utilize berry-derived 
Anthos and exosomal formulation of Anthos (ExoAnthos) for the prevention and 
treatment of a bacterially-driven model of CRC. Similar to the majority of 
individuals that have been diagnosed with CRC in the younger generations, this 
model develops tumors in the distal colon. A major component of the work 
presented here has been to unravel the highly interrelated and complex 
mechanism of action for how Anthos achieves highly significant  reductions in 
tumor burden as well as to determine how Anthos exerts protection against the 
ubiquitous environmental carcinogen benzo[a]pyrene (B[a]P). Although, it should 
be noted that gaining a complete understanding for how Anthos functions would 
need a lifetime in research rather than the finite span that defines an individual’s 
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time as a graduate student. Thus, the picture presented here is but a small albeit 
compelling piece of the overall puzzle. 
CRC 
Classified as the third most common form of cancer diagnosed in men and 
women, CRC is the third leading class for cancer-related deaths within the United 
States. In fact, according to the American Cancer Society, an estimated 140,250 
individuals will be diagnosed and 50,630 will die from CRC in the US in 2018 
alone. Therefore, given the prevalence and lethality of CRC, there is an urgent 
need for investigating not only chemotherapeutic alternatives but also 
chemopreventive strategies for this disease. 
Influences on the development of CRC  
It is estimated that cases of CRC will increase by approximately 60% or 2.2 
million new cases and 1.1 million deaths by 2030 [1]. Several factors have been 
found to impact an individual’s chance of developing CRC including age, race, 
gender [2], lifestyle and diet [3]. According to the American Cancer Society, the 
lifetime risk of developing CRC is about 1 in 22 (4.49%) for men and 1 in 24 
(4.15%) for women. The highest incidence rates have been found in countries 
with high or very high human health indexes (HDI) such as North America, 
Europe, Australia and New Zealand and the lowest incidence rates have been 
found in Africa and South-Central Asia [4]. It should also be noted that although 
the rates of CRC have been increasing recently in other parts of Asia, India has 






Figure 1: Distribution of estimated new cases of cancer and cancer deaths for 




The low rate of CRC in this region has been hypothesized to be linked to variety 
of factors such as the widespread consumption of fruits and vegetables, 
vegetarianism and the use of spices such as turmeric (curry powder), which is 
rich in the protective phytochemical, curcumin [5, 6]. The important role of one’s 
diet on the likelihood of developing CRC was previously identified in a case-
control study in Greece which found that individuals who consumed a diet that 
was high meat/low vegetable versus high vegetable/low meat showed a risk ratio 
of about 8 [7]. Additional, more recent studies assessing the influence of dietary 
vegetable and particularly fruit intake on CRC prevention have found similar 
protective benefits in individuals from Sweden, China, South Korea and the 
United States [8-11] Overall, these epidemiological findings highlight the 
protective role that vegetable and particularly fruit consumption may have against 
the development of CRC and may be associated with the geographic differences 
in incidence noted above. 
Although the incidence of CRC has been decreasing since the mid to late 1980s 
for individuals over 55 years old, a recent study has found a rather disconcerting 
uptick in the CRC incidence for individuals below 55 years old in the US [12]. A 
particularly concerning trend was noted for younger individuals, with individuals 
born circa 1990 having a risk of developing colon cancer that is double that of an 
individual born circa 1950 and for rectal cancer the risk was four-fold higher. 
Moreover, a greater number of the younger cases were found in the distal colon 
as opposed to the proximal colon. This is somewhat surprising considering that 
tumors in the distal colon have been decreasing overall in recent years, while 
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tumors of the proximal colon have become more common in the 55 years or 
older portion of the population [12]. The exact causes for this recent increase in 
younger individuals have yet to be defined. However, a number of factors have 
been shown to contribute to the development of CRC. The below summary 
provides an overview of some of the key environmental as well as genetic factors 
that are related to the topic of this dissertation and that have been found to 
impact the development of CRC.  
The impact of diet and lifestyle on CRC risk 
The important role that diet and lifestyle play not only on one’s overall health but 
on the chance of developing CRC has been found in a number of studies.  
Furthermore, it should be noted that chronic inflammation has been shown to be 
a significant etiological factor in the development of colorectal adenocarcinoma 
[13]. It has been shown in both males and females that a link exists between 
consuming a high inflammatory diet, i.e. a diet rich in animal fat, alcohol et cetera 
and low in fruits and vegetables, and developing CRC [3]. Moreover, results from 
the same study also supported the benefits of an anti-inflammatory diet, which 
include plant-based foods which are a rich source of phytochemicals, over a pro-
inflammatory diet, which includes fried foods, highly processed foods etc., as a 
means of decreasing the risk of developing CRC [3]. Additionally, coffee, which 
contains a variety of bioactive compounds including polyphenols, melanoidins, 
diterpenes, is believed to also lower the risk of developing CRC [14]. 
Epidemiological studies comparing coffee drinkers vs. non-drinkers showed a 
26% lower odds of developing CRC [14].  There also appeared to be a dose-
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dependent trend for both colon and rectal cancers. It was also noted that 
decaffeinated as well as boiled coffee showed an inverse association (OR, 0.82; 
95% CI: 0.68-0.99; P=0.04) and (OR, 0.82; 95% CI: 0.71-0.94; P=0.004), 
respectively [14]. In addition to coffee, it has also been shown that regular green 
tea consumption (at least three times per week for a minimum of 6 months), 
which is a rich source of antioxidant tea polyphenols, reduces the risk of CRC 
(HR=0.54, 95% CI: 0.34-0.86). Furthermore, it was noted that as green tea 
consumption was increased risk of CRC decreased (Ptrend=0.01) [15].  
In addition to dietary influences, another important factor that must be considered 
is the long term use of medications such as statins, aspirin and non-aspirin 
nonsteroidal anti-inflammatory drugs which are also believed to lower the risk of 
developing CRC. For example statins which are believed to inhibit 3-hydroxy-
3methylglutaryl coenzyme A (HMG-CoA) reductase which is overexpressed in 
colorectal cancer cells were associated with a 47% relative reduction in risk of 
CRC [16]. Whereas, NSAIDS, which are believed to act by inhibiting 
cyclooxygenase-2, which has been shown to be upregulated in CRC, was shown 
to yield an adjusted relative risk of 0.5 (95% confidence interval of 0.4-0.7) [17].  
Boundless insight into the complex exchange between the individual and their 
environment and their associated risk of developing CRC has been gained by the 
sheer depth of epidemiological studies conducted to date [18-22]. However, the 
above findings should be interpreted with caution due to the dangers of inferring 
causation from association. Nevertheless, the above studies provide a promising 
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foundation from which the topic of my dissertation, i.e. the use of Anthos as both 
a chemopreventive and chemotherapeutic agent, has been constructed.  
Role of carcinogens 
A variety of environmental carcinogens such as PAHs, PCBs and PCDDs [18] 
have been linked to the development of CRC. One specific class of carcinogens 
that are particularly ubiquitous and relevant though are polycyclic aromatic 
hydrocarbons (PAHs). The PAH, B[a]P, is a byproduct of incomplete combustion 
of organic materials and is commonly found in charbroiled meat, vehicle exhaust, 
coal tar, and tobacco smoke. In addition to these more well-known sources of 
exposure, B[a]P has been found to contaminate a wide array of foods including 
cooked meat (4 ng B[a]P/g, i.e., 4 ppb of cooked meat), as well as kale and 
collard greens (0.5 ng B[a]P/g) [19], with the daily estimated oral intake of B[a]P 
of 40.1 to 60 ng for most individuals in a study comprised of residents of the 
metropolitan area of Washington, DC, USA [19]. It should be noted that the range 
of estimated B[a]P intake for this study went up to 140-160 ng/day [19]. The 
classical mechanism by which B[a]P causes carcinogenesis is by intercalating 
into DNA and ultimately covalently binding of its electrophilic metabolites with 
guanine bases. The most active metabolite of B[a]P, benzo[a]pyrene-7,8-
diolepoxide (BPDE) is classified as a group 1 carcinogen by the International 
Agency for Research on Cancer (IARC) and is the result of the bioactivation of 
B[a]P by enzymes including the cytochrome P450 (CYP) 1A1 and/or 1B1 and 
microsomal epoxide hydrolase (mEH) (1 , 4 , 5 ).  It should be noted that various 
enzymes including members of the glutathione s-transferase (GST), uridine 5'-
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diphospho-glucuronosyltransferase (UGT) and sulfotransferase (SULT) families 
are involved in the detoxification of the intermediates along this bioactivation 
pathway. Intercalation of DNA acts to distort the structure of DNA disrupting the 
copying of DNA, which in turn causes mutations. BPDE has also been found to 
target p53 thereby altering the tumor suppression of cells which may ultimately 
lead to cancer [23].  
Role of bacterial dysbiosis 
 Although bacteria have long been associated with a variety of diseases such as 
diphtheria, tetanus, tuberculosis, typhoid fever and botulism, to name a few, only 
recently has the role of bacteria in carcinogenesis been elucidated. In fact, 
bacteria such as Heliobacter pylori and Enterotoxigenic Bacteroides fragilis 
(ETBF) have been linked to a variety of cancers including gastric and colon 
cancer, respectively. One particular toxin producing bacteria, ETBF has recently 
come to the forefront in its role in colon cancer. Although the gram negative B. 
fragilis bacteria make up a minority when compared to the prevalence of other 
bacterial community members, they cause the majority of anaerobe-associated 
invasive disease cases [24]. A particularly toxic member of the B. fragilis family is 
ETBF. This bacteria secretes the enterotoxin b. fragilis toxin (BFT) which is a 20 
kDa zinc-dependent metalloprotease toxin which indirectly stimulates the 
cleavage of E-cadherin thus leading to increased colonic permeability [25]. 
Additionally, it leads to activation of β-catenin, which further leads to enhanced 
proliferation of cancerous CECs [26]. ETBF induces Stat3/Th17 inflammation 
which further fuels colon tumorigenesis [27]. Interestingly, the BFT toxin, of which 
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three similarly acting isotypes, BFT-1, BFT-2, and BFT-3, have been identified, is 
structurally similar to other bacterial toxins including the tetanus and diphtheria 
toxins [24]. Recent work from the Sears lab shows that patients with the inherited 
disease, familial adenomatous polyposis (FAP), which is caused by as APC 
mutation, are more prone to having patchy bacterial biofilms that were composed 
primarily of Escherichia coli (colibactin producing) and ETBF [28]. Thus, given 
the clinical relevance and pathogenicity, ETBF bacteria is an ideal candidate for 
further research. 
Outline of mutations linked with development of CRC 
In addition to the extrinsic influences discussed above, another key participant in 
the dialogue of colorectal carcinogenesis is genetics. Some of the key genes that 
have been found to influence the development of CRC include TP53, 
KRAS/BRAF [29, 30], EGFR/PTEN [31-33], SMAD7 [34], MLH1 [35], MUTYH 
[36] and the adenomatous polyposis coli (APC) gene [37-40]. 
Both sporadic and hereditary cases of CRC have been attributed to mutations in 
the adenomatous polyposis coli (APC) gene. It has been noted that 34-70% of 
sporadic colon cancer cases feature inactivating mutations in APC particularly in 
the mutation cluster region, with genetic aberrations such as deletions, 
insertions, point and missense mutations detected in the mutation cluster region 
in 72% of the patients studied [37]. It has also been shown that individuals with 
APC gene mutations possess a significantly increased risk for CRC (pooled OR 
of 1.42 and 95% CI of 1.16-1.74 with a P value of 0.00085) [38]. Furthermore, it 
should be noted that APC mutations appear to be more likely to occur with TP53 
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mutations (OR 3.513, 95% CI of 1.212-10.184) and KRAS mutations (OR 1.995, 
95% CI of 0.607-6.554) [40]. 
The important role that the above mutations, especially APC, play in the 
development of CRC has been historically well documented. Moving forward, the 
characterization or “fingerprinting” of an individual’s specific mutations will be key 
in developing personalized therapeutic regimens for each patient. 
           Pathways of genomic instability that can lead to CRC  
It is commonly accepted knowledge that three main molecular pathways of 
genomic instability are involved in the development of CRC and include: the 
chromosomal instability pathway (CIN), the mismatch repair-deficient or 
microsatellite instability pathway (MSI), and the CpG island methylator phenotype 
(CIMP) pathway. 
The CIN pathway, which was originally elucidated by Fearon and Vogelstein in 
1990, is believed to be responsible for most cases of CRC and is observed in 65-
70% of sporadic CRC’s [41]. These cases feature characteristic loss of 
heterozygosity (LOH), sub-chromosomal genomic amplifications and widespread 
aneuploidy. In Fearon and Vogelstein’s seminal 1990 article, they proposed a 
multi-step model for colorectal carcinogenesis [42] (Figure 2). The initiating event 
in adenoma formation is the inactivation of the Adenomatous Polyposis Coli 
(APC) tumor suppressor gene which is followed by activating mutations of KRAS. 
Additional mutations in TGF-β [43], PIK3CA [44], and TP53 [45] pathways then 
drive the subsequent malignant transformation. It should be noted that although 
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APC mutations serve as the initiating event in human and mouse models, 
mutational activation of KRAS is unable to initiate cancer in vivo and only when 
combined with mutant APC will mutant KRAS promote tumor progression, thus 
supporting Fearon’s multi-step model [46]. 
The MSI pathway accounts for approximately 10-20% of all CRCs [47]. Although 
the MSI pathway was originally elucidated for individuals with familial Lynch 
syndrome, most CRCs with MSI are sporadic. In fact, only 3% of all CRCs come 
from Lynch syndrome families [48]. MSI tumors caused by Lynch syndrome are 
associated with germline mutations in DNA mismatch repair (MMR) genes and 
often have KRAS mutations, but never have BRAF mutations. 
Lynch syndrome tumors also typically occur in younger individuals and typically 
have a better prognosis than non-MSI tumors [49]. Approximately 50% of 
sporadic cases of MSI have BRAF mutations and are associated with CIMP, 
unlike Lynch syndrome tumors. As can be expected, sporadic cases of MSI-
associated CRCs typically occur in older individuals[48].  
The CpG island methylator (CIMP) is observed in approximately 30% of CRC 
cases [50]. As its name implies, the CIMP pathway promotes epigenetic 
instability and enables sporadic cancers to methylate the promoter regions of key 
tumor suppressor genes thereby effectively inactivating their expression [51]. In 
fact it is present in all tumors with MLH1 aberrant methylation [52]. CIMP positive 
tumors typically exhibit specific clinicopathological features such as proximal 
location and tend to be more common in older women, are often MSI and poorly 
differentiated. They also tend to have a distinct molecular profile which features 
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low TP53 and high BRAF mutation rates [53]. Furthermore, cases of colorectal 
cancer that develop via the CIMP pathway tend to develop from sessile serrated 
adenomas rather than adenomatous polyps [54]. 
Current standard of care  
As with most cancers current treatment options for individuals diagnosed with 
CRC include one or more of the following options: surgery, radiation therapy, 
non-targeted chemotherapy, or targeted therapy. 
According to the American Cancer Society, drugs currently approved by the U.S. 
FDA for the treatment of CRC include: capecitabine, fluorouracil (5-FU), 
irinotecan, oxaliplatin, and trifluridine/tipiracil. One or more of these 
chemotherapeutic drugs are most often given over the course of treatment with 
more common treatment regimens with these drugs including: 5-FU, 5-FU with a 
vitamin called leucovorin which improves the efficacy of 5-FU [55], capecitabine, 
5-FU with leucovorin and oxaliplatin (FOLFOX), 5-FU with leucovorin and 
irinotecan (FOLFIRI), capecitabine with either irinotecan (XELIRI or CAPIRI) or 


























A variety of side effects are associated with taking the standard 
chemotherapeutic drugs including: nausea, vomiting, fatigue, diarrhea, 
suppression of bone marrow, immunosuppression, and liver damage [56, 57]. 
Given the current limitations and these side effects associated with the current 
standard of care, additional treatment options are warranted.  
In addition to non-targeted chemotherapeutic treatment options, targeted 
therapies are also common, including: bevacizumab, regorafenib, ramucirumab 
and ziv-aflibercept, which are antiangiogenesis therapies, and cetuximab and 
panitumumab which are anti- EGFR therapies [58]. Although, one of the key 
benefits of targeted therapy is the reduction in off-target side-effects, they are 
also accompanied with side-effects including gastrointestinal perforation, arterial 
thromboses which include strokes and myocardial infractions [59].  
In addition to the above therapies, within the past year the FDA has approved 
use of the immune checkpoint, PD-1, inhibitor, pembrolizumab for the treatment 
of CRC cases that have mismatch repair deficient (dMMR) and microsatellite 
instability high (MSI-H) abnormalities. However, like the previously mentioned 
therapies, pembrolizumab treatment has been associated with immune related 
adverse effects such as inflammation of the lungs, colon, kidney, thyroid and 
pituitary gland [60]. Therefore, there remains significant room for the 
development of cost-effective, non-toxic prevention and treatment options.  
Treatment options for individuals diagnosed with colon cancer are typically 
dependent upon their specific stage. Additional factors such as age and other 
health problems are also considered for the optimal treatment plan [61]. In most 
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cases, when the cancer has not spread to distant sites, surgery is typically the 
first main treatment. For more advanced-stage cancers, an adjuvant 
chemotherapy may also be recommended. Adjuvant chemotherapy may be 
recommended as early as stage II, but is more typically recommended beginning 
in stage III [61]. For the more advanced stage IV cases of colon cancer where 
the disease has spread to distant organs and tissues, a key component of the 
treatment is chemotherapy since in most cases surgery will not cure these 
individuals. Since the early 2000’s, 5 new drugs have been approved for the 
treatment of stage IV colon cancer. These drugs fall into one of the three 
following classes: multi-kinase inhibitors, anti-angiogenic (Bevacizumab, Ziv-
aflibercept), or EGFR blockers (Cetuximab, panitumumab) [62].  
Key limitations in the current standard of care include, but are not limited to the 
following areas: off-target side effects, the current gap that exists in adjuvant 
therapy for stage I and especially stage II cancers of the colon, and limitations in 
treatment options for older individuals. Given these limitations, research 
investigating alternative preventative treatment options is of great importance. 
Familial Adenomatous Polyposis (FAP) 
The majority of CRC cases originate from previously benign adenomatous 
polyps. This process of transformation from benign polyp to malignancy typically 
takes decades to occur, with approximately 85% of colorectal cases occurring 
after the age of 55 years, according to data acquired by the U.S. preventive 
services task force. A small subset of CRC cases stem from familial syndromes 
such as Lynch syndrome, FAP, attenuated FAP (AFAP), MUTYH-associated 
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polyposis (MAP) and rare syndromes such as hyperplastic polyposis, Peutz-
Jeghers syndrome (PJS) and juvenile polyposis syndrome [63, 64]. 
FAP is an autosomal dominant pre-cancerous colorectal condition with an 
incidence at birth of around 1/8,300 [65]. FAP occurs with equal frequency in 
both males and females and accounts for less than 1% of colorectal cases [65]. 
The disease may begin as early as the teenage years, with colon cancer 
developing on average by the age of 39 years old. Furthermore, approximately 
7% of individuals with FAP will develop CRC by the time they reach 21 years old 
and 95% of FAP sufferers will develop CRC by the time they reach the age of 50 
[66]. FAP is caused by mutation(s) in the APC gene. The APC gene, which is 
located on chromosome 5q21 is a tumor suppressor gene that encodes for a 312 
kDa protein with 2843 amino acids. It is expressed in a variety of fetal and adult 
tissues including colorectal epithelium as well as mammary [67]. 
Mutation(s) in the APC gene, 60% of which are nonsense mutations, have been 
shown to accelerate the initiation of the adenoma-carcinoma sequence since the 
inactivation of APC serves as the initial step in the development of CRC in FAP 
[65]. The APC protein serves as a scaffolding protein which affects cell adhesion 
and migration. The mammalian form of APC contains multiple binding domains 
including an oligomerization domain, an armadillo repeat domain, a repeat 
domain consisting of between 15-20 residues which is important for binding to β-
catenin, SAMP repeats which are important for axin binding, a basic domain that 
is responsible for microtubule binding, and finally C-terminal domains, which bind 
the proteins, EB1 and HDLG [68]. 
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APC interacts with a variety of other key proteins such as the Wnt/Wg pathway 
members, β-catenin and axin, the Rac guanine-nucleotide-exchange factor 
(GEF) Asef1, the cytoskeletal regulators EB1 and IQGAP1, as well as 
microtubules [69]. Mutations in APC lead to the accumulation of β-catenin in the 
cytoplasm where it binds and activates the T-cell factor (TCF) and lymphoid 
enhancer factor (LEF) families of transcription factors altering the expression of 
genes that encode for the metalloprotease matrilysin, ephrins, cyclin D1 and the 
proto-oncogene c-myc which in turn lead to changes in cellular proliferation, 
differentiation and migration [70].  
If left untreated, individuals with FAP will develop CRC by their forties [71]. As 
discussed above, APC plays a key role in the multi-step model of colorectal 
cancer proposed by Fearon and Vogelstein (Figure 1). The disease is 
characterized by the development of hundreds to thousands of adenomatous 
colon polyps. Currently, the only approved primary modality of treatment for FAP 
is prophylactic cancer-preventive colorectal surgery. Given the lack of non-
invasive treatment options and the role of FAP in CRC development, additional 
treatment options are of great need. 
Anthos: a promising treatment for FAP and colorectal cancer 
Several plant-derived compounds such as quinine, codeine, paclitaxel, 
apomorphine, have been an invaluable source of medicines for humans 
throughout history. One particular family of compounds that has sparked recent 





One particular class of relevance is the flavonoids which is one of the largest 
groups of secondary metabolites with well over 6000 molecules [72]. Compounds 
classified as flavonoids, which all share a common core 15-carbon skeleton, can 
be divided into 6 major classes: flavanols, flavonols, flavonones, flavones, 
isoflavones and anthocyanins. Flavonoids are commonly synthesized by plants in 
order to fulfil a variety of protective functions ranging from chromatic attractants 
for pollinators, deterrents for pests, protectants against UV-B, as well as 
antimicrobial agents [73]. 
Anthocyanins and anthocyanidins 
Found in dark-colored vegetables, fruits, grains and flowers, anthocyanins, which 
comes from the Greek words Anthos for flower and kyanos for blue, provide the 
characteristic red, purple and blue hues to eggplant, blueberry, black rice and 
black sesame seeds. Over 600 structurally distinct anthocyanins have been 
identified in nature [74, 75]. It should be noted that anthocyanins are known as 
anthocyanidins when non-glycosylated. Of the seventeen anthocyanidins found 
in nature, only six, including the glycosylated forms of cyanidin (Cy), delphinidin 
(Dp), petunidin (Pt), peonidin (Pn), pelargonidin (Pg) and malvidin (Mv), are 
widely distributed [76]. The above anthocyanidins are typically bonded to 
glucose, galactose, arabinose, rhamnose, and xylose in either a mono-, di- or tri-
saccharide form. An additional layer of complexity is provided by the fact that the 
sugar moieties can also be acylated by various aromatic or aliphatic acids. The 
various combinations/permutations of anthocyanidins and their pendant sugars 
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vary from plant to plant. Importantly, it should be highlighted that the active 
component of the compounds is the central anthocyanidin moiety.  
The core structure of anthocyanidins (Figure 3) is composed of an aromatic ring 
A that is bonded to a heterocyclic ring C containing oxygen that is bound via 
carbon to a third aromatic ring B. The substituted flavonoids contain a flavylium 
cation, which due to its conjugated double bonds, absorbs light with a 
characteristic peak range between 500 – 550 nm. The specific hue(s) associated 
with each anthocyanin depend upon the degree of hydroxylation and 
type/number of substitutions. A total of 17 anthocyanidins have been isolated to 
date [77]. 
The specific anthocyanin fingerprint varies between each type of fruit, vegetable, 
grain or flower.  For example, fruits such as red currants and elderberry contain 
primarily cyanidin, whereas blueberry, bilberry and jamun (Indian black plum) 
contain 5 anthocyanidins - cyanidin, delphinidin, petunidin, peonidin and 
malvidin, all in their glycosylated forms. Bilberry in particular contains a native 
mixture of delphinidin, cyanidin, malvidin, peonidin, and petunidin in a relative 
ratio of 33:28:16:16:7 [78]. As noted above, in addition to variations in the core 
anthocyanidin structure, variations in the pendant sugar moieties also varies from 
plant to plant. For example, even though red currant and blackcurrant are closely 
related, red currant contains mainly mono- and diglycosides, whereas black 
currant contains primarily rutinosides and only a minor glycoside component [79]. 




Role of anthocyanins within plants 
Within plants, anthocyanins accumulate in vacuoles of a variety of cells in both 
vegetative as well as reproductive organs. Most of the 17 anthocyanidins isolated 
to date are found only in the reproductive structures of the plants whereas only 
six anthocyanidins (cyanidin, peonidin, delphinidin, petunidin, malvidin and 
pelargonidin) have been found in the vegetative organs [80]. 
Furthermore, anthocyanins are synthesized in the branch of the flavonoid 
biosynthetic pathway that is involved in the synthesis of isoflavonoids and 
flavonols [77]. Anthocyanins are thought to play a variety of different functions 
within plants ranging from as antioxidants, sunscreens, and even as metal-
chelating agents and in delaying foliar senescence under conditions of mineral 
imbalance or macronutrient deficiency [77]. Given their beneficial roles in plants, 
one can easily hypothesize that benefits may be gained from their consumption 
by humans.  
           Anthocyanin absorption, stability, and digestion  
Absorption of anthocyanidins and anthocyanins by gut epithelial cells occurs via 
different mechanisms due to the structural differences. Due to the hydrophilicity 
added by the sugar residues on anthocyanins they must utilize facilitated 
transport mechanisms whereas (the sugar-free) anthocyanidins are more 
hydrophobic and are able to be passively absorbed by gut epithelial cells [81]. In 
fact, the hydrophobicity of a compound, expressed in terms of its partition 
coefficient (log octanol/water) is often used as a predictive means to determine 
the ability of a compound to passively diffuse across a biological membrane.  
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Interestingly, it has been found that nonenzymatic deglycosylation does not occur 
in the human body for polyphenols such as quercetin [82]. Additionally, only 
polyphenols with attached glucose, arabinose or xylose and not rhamnose 
moieties can serve as potential substrates for human β-glucosidases. Therefore, 
rhamnose moieties can only be cleaved once they reach the colon where they 
can serve as a substrate for bacterial α-rhamosidases [81]. This limitation may 
have important ramifications for the activity of rhamnose-containing anthocyanins 
in diseases of the small intestine or in diseases where digestive transport time is 
expedited such as inflammatory bowel disease (IBD). 
Another important topic that must be addressed in the discussion of anthocyanin 
metabolism is the role of deconjugation and reconjugation reactions. Although 
anthocyanins do not appear to undergo as extensive of metabolism as other 
flavonoids, it will be discussed for completion since it occurs and is a variable 
that must be considered [83]. Following hydrolysis, the free aglycones undergo 
metabolic processing in the form of methylation, sulfation, glucuronidation or a 
combination of the above reactions [84, 85]. Based on the structural differences 
between anthocyanins versus anthocyanidins, the impact that conjugation has on 










































Figure 3: Structures for the five anthocyanidins (the active moiety of 









Overall, one should understand that a competition between the uptake of 
anthocyanidins and the excretion of more hydrophilic anthocyanins as well as 
their conjugated counterparts exists. Therefore, one could posit that by 
administering anthocyanidins either in their pure form or by nano-delivery 
systems to enhance oral bioavailability, one would enhance their therapeutic 
potential in the clinical setting.   
Data from In vitro work 
A variety of in vitro studies have been conducted in order to investigate the 
impact that anthocyanins derived from various sources have on colon cancer cell 
lines. Berry extracts containing anthocyanins isolated from cowberry, strawberry, 
bilberry, and blueberry have been shown to inhibit the proliferation of the colon 
cancer cell line HCT116 [86]. Furthermore, anthocyanin rich extracts derived 
from fruits including bilberry (Vaccinium myrtillus L.),  grape (Vitis vinifera), and 
chokeberry (Aronia meloncarpa E.) have been shown to inhibit the growth of the 
colon cancer cell line HT-29 cells but not the non-tumorigenic NCM460 colon 
cells [87].  
A variety of potential mechanisms have been suggested in the literature. For 
instance, anthocyanins isolated from the grape, Vitis coignetiae Pulliat were 
shown to induce caspase-dependent apoptotic cell death, activate p38-MAPK 
and suppress Akt in HCT-116 colon cancer cells [88]. Moreover, pelargonidin, 
found in a variety of berries such as strawberry and raspberry, was shown to 
inhibit proliferation of the colon cancer cell line HT-29 and induce apoptosis and 
G2/M cell cycle arrest by the intrinsic apoptotic pathway [89]. Additionally, 
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delphinidin, found in fruits like blueberry, has also been shown to induce 
apoptosis and G2/M cell cycle arrest in HCT116 colon cancer cells [90]. The 
mechanism by which delphinidin led to G2/M arrest and apoptosis in HCT116 
cells is believed to be due to suppression of the NF-κB pathway [90]. 
Anthocyanins and anthocyanidins have also been shown to induce significant 
oxidative DNA-strand cleavage in the presence of dithiotheritol (DTT), but not 
DMSO, which serves as a free radical scavenger, at physiological pH. It was 
further hypothesized that at pH 7.5, the quinones formed from anthocyanins and 
anthocyanidins autoxidize to yield hydrogen peroxide [91]. Fe 3+ is believed to 
increase anthocyanin-induced cleavage since when it is reduced it is able to 
stimulate the production of hydroxyl radicals from hydrogen peroxide. The 
resulting hydroxyl radical, rather than hydrogen peroxide, is believed to induce 
the cleavage of DNA [91]. Only at high concentrations were anthocyanins also 
shown to inhibit topoisomerase relaxation [91]. 
Data from in vivo studies 
The beneficial effects of anthocyanins shown in vitro have also been shown to 
exist in vivo. For instance, the anthocyanin-rich soybean fraction containing 
cyanidin-3-glucoside, delphinidin-3-glucoside and petunidin-3-glucoside, was 
shown to significantly decrease the number of intestinal tumors in ApcMin/+ mice 
fed a 0.5% anthocyanin-rich extract compared to control animals [92]. 
Furthermore, mucosal expression of cytosolic phospholipase A2 and 
cyclooxygenase-2, which are both involved in inflammatory response, were 
significantly decreased in mice treated with 0.5% anthocyanin-rich extract [92]. 
25 
 
Additionally, an in vivo study in ApcMin/+ mice using 0.3% oenocyanin, which 
contains the 3-glucosides of delphinidin, cyanidin, petunidin, peonidin, and 
malvidin extracted from grape pomace, showed a reduction in adenoma burden 
and reduction in proliferation index in colonic adenomatous crypts [93]. A 
reduction in the expression of Akt, which is involved in a variety of cellular 
processes including glucose metabolism, apoptosis, cellular proliferation, 
transcription and migration, was also observed in 0.3% oenocyanin-treated mice 
[93]. Interestingly, oenocyanin anthocyanins and their metabolites were not found 
in the plasma but rather only in the urine and intestine [93]. Moreover, in a mouse 
model of colitis, dextran sulfate sodium (DSS) induced histological damage and 
weight loss were significantly improved in mice administered a red raspberry 
anthocyanin-rich fraction [94]. In the same study, anti-inflammatory properties 
were shown in vivo with overall reductions in the expression of cyclooxygenase-2 
(COX-2), interleukin-1 beta (IL-1β), IL-6 and inducible nitric oxide (iNOS) in red 
raspberry anthocyanin-rich fraction treated RAW264.7 cells [94]. 
A study assessing the impact of dietary cyanidin-3-glucoside and an anthocyanin 
mixture from bilberry on the development of adenomas in an ApcMin/+  mouse 
model for FAP [95] showed that ingestion of cyanidin-3-glucoside or a bilberry 
derived anthocyanin mixture led to a reduction in adenoma load in a dose-
dependent fashion. It should be noted that although significant reductions in 
adenoma numbers were seen for cyanidin-3-glucoside (p< 0.001) and 
Mirtoselect® bilberry anthocyanins (p<0.05), the doses that were used were 0.3% 
of the diet which is equivalent to 450 mg/kg/day or 2.6 g/80 kg human dosage, 
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when the authors extrapolated using the dose/surface area comparison between 
species [96]. When the Mirtoselect ® native bilberry mixture was extrapolated 
back to the amount of fresh berries that would need to be consumed, it was 
concluded that an individual would need to consume ~740 g of fresh bilberry a 
day [95]. Given the large nature of the dose used in the study, which is further 
complicated due to the presence of high sugar content (about 60% in blueberry), 
it is clear that one would need to lower the dose by identifying the active 
principles as well as eliminate large sugar content in order to be a clinically-viable 
option.  
Data from clinical trials  
A limited number of clinical trials have been undertaken to assess the impact that 
anthocyanins, taken in the form of either berry powder or as an anthocyanin-rich 
standardized bilberry extract, has on CRC. The first study was a clinical trial 
assessing whether an anthocyanin-rich standardized bilberry extract (Mirtocyan®) 
administered to patients (1.3, 2.8 or 5.6 g, containing 0.5-2.0 g anthocyanins) 
daily for 7 days before surgery would induce pharmacodynamics changes that 
would be in agreement with chemopreventive efficacy [97]. Results from the 
study showed that a 7% decrease in proliferation was observed in tumor tissues 
taken from patients when compared to their pre-intervention values. Another 
clinical trial investigating the impact of freeze-dried blackberry powder (60 g/day, 
for 1 to 9 weeks) in colorectal cancer patients showed beneficial changes in GM-
CSF and IL-8, markers for proliferation and apoptosis respectively [98].  
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A clinical trial assessing the impact of black raspberry powder on biomarkers of 
colorectal tumor development showed that the methylation patterns of three Wnt 
inhibitors including WIF1, SFRP2, SFRP5 and the developmental regulator 
PAX6a were protectively modulated in normal and in colorectal tumor tissues in 
patients receiving the black raspberry powder (60 g/d) for an average of 4 weeks. 
Furthermore, the protective modulation of methylation was associated with 
decreased expression of the enzyme that transfers methyl groups to the cytosine 
nucleotides in genomic DNA, DNA (Cytosine-5-)-Methyltransferase 1 (DNMT1) 
[99]. Interestingly, the authors also noted that black raspberry powder decreased 
β-catenin as well as protectively modified Ki-67, TUNEL, CD105, as well as 
DNMT1 in colorectal tissues from the 20 patients. CD105 and DNMT1 were also 
found to be modulated in adjacent normal tissues. The impact on β-catenin and 
E-cadherin expression was also shown to be dose dependent, with the high dose 
(~ 4 weeks) black raspberry powder treatment yielding greater impact than the 
low dose (~ 2 weeks) black raspberry powder treatment [99]. 
In addition to studies on CRC, anthocyanin-rich bilberry extract has also been 
shown to reduce the amount of pro-inflammatory cytokines including TNF-α and 
IFN-γ in colon biopsies from patients with ulcerative colitis (UC). Furthermore, 
serum levels from UC patients that were successfully treated with anthocyanin-
rich bilberry extract had enhanced levels of immunoregulatory IL-10 and the Th-
17 cell specific cytokine IL-22 and reduced levels of TNF-α and IFN-γ [100]. In 
another clinical trial testing the impact of a standardized anthocyanin-rich bilberry 
extract on UC disease activity showed that after 6 weeks of treatment, 63.4% of 
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patients achieved remission and 90.9% of patients showed a response. It was 
also noted that fecal calprotectin levels were also decreased during the 
treatment, which further suggests that intestinal inflammation was reduced [101]. 
It should be noted that all of the anthocyanin-mediated colorectal cancer clinical 
trials published to date have been conducted using anthocyanins rather than 
anthocyanidins. Although the bioavailability of anthocyanins is very low in the 
plasma (<1%), greater bioavailability has been found in colonic tissues [102]. 
This suggests that they may have greater potential since they can directly 
interact with the colon tissue. Additionally, one can posit that additional benefits 
in uptake, if administered in the aglycone form (i.e., as anthocyanidins) or by 
utilizing a nano drug delivery vehicle such as bovine milk-derived exosomes (i.e. 
ExoAnthos).  
Exosomes 
Size, history, sources 
Exosomes are defined as membrane-bound vesicles that range in size from 30-
100 nm, in diameter, feature a density in sucrose gradients of 1.13-1.19 g/ml, are 
highly enriched with tetraspanin molecules and are of endocytic origin [103]. 
Exosomes were discovered in 1983 by Pan and Johnstone. In 1989, Pan and 
Johnstone named the vesicles exosomes [104]. Since their identification, 
exosomes have been isolated from essentially all biological fluids such as saliva, 





Exosomes are initially formed via a process of endocytosis, with the 
internalization of the cell membrane to yield endosomes (Figure 4). Following the 
formation of endosomes, many small vesicles are formed inside the endosome 
by invagination of parts of the endosomal, multi-vesicular body (MVB), 
membrane. The MVBs then fuse with the cell membrane thereby releasing the 
intraluminal vesicles into the extracellular space.  Following their release, these 
vesicles are referred to as exosomes.  
Exosome composition  
Exosomal membranes are primarily composed of lipids and proteins and are 
enriched with lipid rafts [106]. The lipid composition of exosomes is distinctively 
rich in cholesterol, ceramide, sphingomyelin, and phosphatidylserine [107]. 
However, exosomes contain minimal to no lysobisphospatidic acid (LBPA), which 
distinguishes them from MVBs’ intraluminal vesicles (ILVs) [107]. Furthermore, 
the fatty acids in exosomes tend to be saturated or monounsaturated, which in 
addition to the high concentration of cholesterol is believed to lead to the lateral 
segregation of these lipids into exosomes during their formation [108]. Results 
from proteomic studies suggest that exosomes contain specific proteins from 
endosomes, plasma membrane, and cytosol [109]. Examples of proteins from the 







Figure 4: Classic pathway of exosome formation. After endocytosis, endosomes 
are formed via the internalization of the cell membrane (sidedness noted in the 
diagram as blue for the initial internal face and black for the initial external face). 
A process of invagination of the endosome yields smaller bodies inside the MVB, 
which can proceed to processing via the golgi apparatus, be released via 


















Proteins originally associated with the plasma membrane include tetraspanins, 
such as CD63, CD81 and CD37. It should be noted that exosomes contain very 
few proteins from other intracellular organelles such as the nucleus, mitochondria 
and Golgi [107].  
Exosome cargo 
In addition to proteins, exosomes have been found to carry as cargo within their 
lumen, that include mRNA, miRNA, small noncoding RNA species such as 
structural RNAs, tRNA fragments, vault RNA, small interfering RNAs, RNA 
transcripts that overlap with protein coding regions and repeat sequences [108]. 
More recent data indicate the presence of some DNA as well [110]. The RNA 
cargo contained within exosomes can either be taken up by neighboring cells or 
transported by the circulating exosomes and taken up by distant cells. Ultimately, 
the RNA cargo in exosomes is believed to function as a form of genetic 
exchange between cells [106]. 
Exosome role in cell to cell communication 
 Once called the “garbage bag” of cells, exosomes have been found to play an 
important role in cell to cell communication.  After finding that mRNAs and 
miRNAs were present in exosomes derived from mast cells, it was also found 
that the mRNA in these exosomes were transported to recipient cells and 
following uptake were translated into proteins thus providing evidence for the 
ability of exosomes to transfer of genetic material [111]. It was noted that not all 
mRNAs that were abundant in the secreting cells were packaged into exosomes 
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thereby suggesting that specific targeting machinery for mRNAs may exist [111]. 
It has also been shown that tumor-derived exosomes can both suppress the 
function of immune cells by promoting the differentiation of regulatory T 
lymphocytes or by inducing apoptosis of activated cytotoxic T cells [112]. 
Exosomes can also induce immune responses by transferring tumor antigens to 
dendritic cells and to present tumor antigens [113]. Interestingly, it has been 
found that exosomes can fuse especially well with the plasma membranes under 
acidic conditions mimicking those of the cancer cell microenvironment [114].  
           Exosomes as therapeutics                                                                                             
Special interest in the application of exosomes for diagnostic as well as drug 
delivery purposes has recently taken root within the scientific community. A key 
area of research within our laboratory is in utilizing exosomes as a drug delivery 
vehicle. Prior to the work conducted in this laboratory the primary source of 
exosomes for drug delivery purposes was from cell culture media and serum. In 
order to overcome the obvious limitations posed by these sources such as 
quantity, safety, cost and translatability, our laboratory pioneered the use of 
exosomes derived from bovine milk [115, 116]. Not only does bovine milk provide 
a scalable source of exosomes, it also exhibits cross-species tolerance. 
Furthermore, no adverse immune or inflammatory responses have been found 
[117].  
Exosomes derived from raw bovine milk can effectively deliver a variety of both 
hydrophilic as well as lipophilic compounds such as curcumin, withaferin A 
(WFA), paclitaxel, celastrol and doxorubicin.  Moreover, tumor targeting of the 
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exosomes with folic acid was shown to increase biological efficacy. Exosomal 
formulations containing WFA, celastrol, or curcumin have shown increased 
efficacy over drug alone in both in vitro and in vivo against lung and breast 
cancer [115, 116]. Prior to the body of studies contained within this dissertation 
no experiments were undertaken with colon cancer. In addition to the role of the 
exosomes as a drug delivery vehicle, they are also believed to deliver an 
additional “payload” of their own. For instance, our laboratory has identified the 
presence of immune-related miRNAs such as miR-146a, -155, -181a and -223 in 
bovine milk derived exosomes [115].  
 
Overall Goals of Doctoral Research Project 
The overarching goal of my doctoral work has been to investigate the use of 
bilberry- derived Anthos as both a chemopreventive and chemotherapeutic agent 
in bacterially-induced CRC and to study how Anthos modulate the influence of 
the environmental carcinogen B[a]P on the balance between phase I and II 
enzymes. In order to accomplish this goal, my research project was divided into 
three specific aims, the interwoven nature of which is highlighted in each of the 
subsequent chapters: 
 Aim 1: Determine anti-proliferative efficacy of optimal mixture of Anthos against 
colon cancer and normal cells in vitro.  
 Aim 2: Determine efficacy of Anthos against colorectal cancer using a bacteria-
driven ApcMin/+ ETBF mouse model.  
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 Aim 3: Determine the mechanistic influence of Anthos on ETBF and B[a]P in 
CRC. 
This dissertation has been written with the goal of submitting the findings for 
publication in peer reviewed journals. Thus, chapters two to four are intended to 
be able to exist independently, with the introductory and summary chapters 
aiming at forming the foundation for the subsequent chapters with the summary 



















NOVEL INSIGHT INTO THE PREVENTION AND TREATMENT OF COLORECTAL CANCER AND 




Colorectal cancer (CRC) is the third leading type of cancer diagnosed and third 
leading cause of cancer-related deaths within the United States each year. 
According to the American Cancer Society, an estimated 140,250 individuals will 
be diagnosed and 50,630 will die from CRC in the U.S. in 2018 alone.  Although 
the overall incidence of developing CRC  has been decreasing since the mid to 
late 1980s for individuals over 55 years old, a recent study has uncovered a 
disquieting increase in the CRC incidence for individuals below 55 years old [12]. 
Although much progress has been made in combating the disease due to 
advancements made in early detection of CRC, clinically-effective 
chemopreventive measures are still of great need. 
Familial adenomatous polyposis (FAP) 
The majority of CRC cases originate from previously benign adenomatous 
polyps. This process of transformation from benign polyp to malignancy typically 
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takes decades to occur, with approximately 85% of CRC cases occurring after 
the age of 55 years, according to data acquired by the U.S. preventive services 
task force. A small subset of CRC cases stem from familial syndromes. One such 
precondition for colorectal cancer is FAP. FAP is an autosomal dominant pre-
cancerous colorectal condition with an incidence at birth of around 1/8,300 [65] 
that is caused by mutation(s) in the adenomatous polyposis coli (APC) gene. 
FAP occurs with equal frequency in both males and females [65]. The disease 
may begin as early as the teenage years, with colon cancer developing on 
average by the age of 39 years. Furthermore, approximately 7% of individuals 
with FAP will develop CRC by the time they reach 21 years and 95% of FAP 
sufferers will develop CRC by the time they reach the age of 50 [66]. The only 
currently approved standard of care for the treatment of FAP is surgical resection 
of the colon [118]. Even after removal of the colon, individuals with FAP are still 
at risk for developing adenomas at other sites [118]. Given the limited treatment 
options for FAP and need for clinically- effective chemopreventive measures for 
CRC, there is a need for additional research for better treatment and prevention 
methods.  
Previous work in chemoprevention of FAP and CRC 
 A wide variety of compounds have been considered in both pre-clinical and 
clinical populations for the prevention of CRC and/or FAP. Clinical trials 
conducted with chemopreventive agents for CRC include non-steroidal anti-
inflammatory drugs such as aspirin [119] and cyclo-oxygenase-2 (COX-2) 
inhibitors, calcium [120], vitamin D [121], folic acid [122], and dietary phenolics 
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such as resveratrol [123], curcumin [124], green tea extract [125], soy 
isoflavones [126] , black raspberry powder [99], pomegranate extract [127] and 
bilberry extract [97]. However, the application of these interventions either were 
deemed ineffective or required large dosages [128, 129]. Therefore, identification 
of plant bioactives present in the human environment for improved clinical 
translation is of utmost importance.  
 
Anthocyanins/Anthocyanidins 
Throughout history, plants have served as an invaluable source of medicines 
including but not limited to paclitaxel, quinine, and digoxin to name a few. One 
particular class of compounds, the anthocyanins, have recently been of great 
interest in the scientific and medical community due to their reported therapeutic 
activities including anti-inflammatory [94], chemopreventive and 
chemotherapeutic [86, 130], obesity control, cardiovascular disease prevention, 
and alleviation of the symptoms of diabetes [131]. Anthocyanins, which come 
from the Greek words Anthos for flower and kyanos for blue, are  ubiquitous plant 
pigments that provide the characteristic red, purple and blue hues to vegetables 
(eggplant, purple cabbage), fruits (berries), grains (black rice, purple corn) and 
flowers (hibiscus). In fact, over 600 anthocyanins have been identified at the 
current time. Anthocyanins feature an aryl-substituted chroman ring system. 
Differences between each specific anthocyanin is dependent upon 
functionalization group(s)  at the 3 and 5 prime locations and the composition of 
the pendant sugars. Furthermore, the active moiety of anthocyanins, 
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anthocyanidins are devoid of the sugar residues but feature the same key central 
ring structure and various permutations of hydroxyl, hydrogen and methoxy 
functional groups (Chapter 1, Figure 3).   
Studies from our own laboratory as well as others have shown therapeutic 
activity of anthocyanins against a variety of cancers including but not limited to 
breast, lung, esophageal, skin and CRC [130, 132]. One such study by Cooke et 
al. [95] showed that ingestion of cyanidin-3-glucoside or a bilberry-derived 
anthocyanin mixture showed a modest reduction in adenoma in CRC in a dose-
dependent fashion. This, however, required large doses (450 mg/kg/day) which 
would translate to 2.6 g/80 kg person. When the native bilberry extract 
(Mirtoselect) was extrapolated to the amount of fresh berries that would need to 
be consumed, it was concluded that an individual would need to consume ~740 g 
of fresh bilberry a day. Given the large nature of the dose used in the study, 
which is further complicated by the presence of high sugar content (about 60%), 
it is clear that one would need to lower the dose by identifying the active 
principles for clinical translatability. Use of berry extracts can reduce doses and 
elimination of the sugars would overcome these concerns. Previous work from 
our group has shown that anthocyanidins yield greater potency in vitro and in 
vivo against lung cancer [78, 133]. The goal of the series of experiments 
contained within this chapter was to elucidate whether Anthos would be an 
efficacious treatment in preventing and treating FAP and a bacterially-induced 




Materials and methods 
Anthocyanins and anthocyanidins 
The anthocyanin, delphinidin 3,5-diglucoside was a kind gift from Dr. Inder P. 
Singh of the National Institute of Pharmaceutical Education and Research (S. A. 
S. Nagar, India). The individual anthocyanidins, cyanidin, delphindin, petunidin 
and malvidin were purchased from Chromadex (Irvine, CA). The native mixture of 
anthocyanidins (or Anthos) isolated from standardized bilberry extract, with purity 
of >80% was generously provided by 3P Biotechnologies, Inc. (Louisville, KY). 
 
Isolation of bilberry-derived Anthos 
The native bilberry Anthos was further enriched using C18 Sep-Pak cartridges 
(Waters, Milford, MA). Anthos were eluted in acidified (0.1% HCl) ethanol. The 
enriched extract was then dried using a Savant SC210A Speed-Vac 
(ThermoFisher Scientific, Waltham, MA) and stored under argon at -20 °C. Purity 
was verified using HPLC-PDA-UV. Briefly, 15 µl samples were analyzed using a 
Shimadzu Premier C18 reverse-phase column (250x4.6 mm i.d., 5 µm). Mobile 
phase A was composed of water: formic acid: acetonitrile (87:10:3) and mobile 
phase B was composed of water: formic acid: acetonitrile (40:10:50). The flow 
rate was 0.6 ml/min and the gradient condition was 0-5 min 5% B; 5-15 min 15% 
B; 15-20 min 25% B; 20-30 min 35% B; 30-40 min 45% B; 40-45 min 100% B; 
45-50 min 5% B. Detection of Anthos was at 520 nm by PDA-UV and total 
Anthos concentration was calculated using a standard curve. The reference 
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compounds were purchased from Chromadex (Irvine, CA) and Cayman 
Chemical Company (Ann Arbor, MI). 
 
Cells, culture conditions and treatments 
The APC wild-type HCT 116 (ATCC® CCL-247™) colon cancer cell line and 
CCD-18Co colon (ATCC® CRL-1459™) normal cells were acquired from 
American Type Culture Collection (Manassas, VA). The APC mutant colon 
cancer cell line HT-29 (ATCC® HTB-38D™) was a kind gift from Dr. Nobuyuki 
Matoba (University of Louisville). HCT-116 and HT-29 cells were maintained in 
McCoy’s 5A medium (Gibco, Grand Island, NY) supplemented with 10% FBS, 
100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere 
containing 5% CO2 at 37°C. CCD-18Co cells were maintained in MeMα (Gibco, 
Grand Island, NY) supplemented with 20% FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin in a humidified atmosphere containing 5% CO2 at 37 °C. 
 
Measurement of cell viability 
The cytotoxicity of individual anthocyanins and anthocyanidins and the Anthos in 
colon cancer and normal cell lines was assessed by enzymatic reduction of the 
tetrazolium dye MTT. Briefly, 3.0 x103 cells/well were grown in a 96-well tissue 
culture plates and were then exposed to varying concentrations of test agents or 
vehicle for 24 h after seeding. After 72 h treatment, cells were incubated with 5 
mg/ml MTT reagent for 2 h. The resulting formazan crystals were then solubilized 
in dimethyl sulfoxide and spectrophotometrically measured at 570 nm (Bio-rad, 
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Philadelphia, PA). IC50 values were then determined using Calcysyn software 
version 2.1 (Biosoft, Cambridge, England).   
 
Western-blot analysis  
For western-blot analysis, 50 µg of protein from in vitro and in vivo tissue lysates 
was resolved using gel electrophoresis and electrotransferred to polyvinylidene 
difluoride membranes by semi-dry transfer (Biorad Trans-blot SD, Hercules, CA). 
Blots were blocked with 4% dry powder milk or BSA for 1 h and then incubated 
with primary antibodies for p-EGFR (Y845), p-EGFR (Y1068), p-EGFR (Y1173), 
total EGFR, p-Src (Y418), total Src, pSTAT3 (Y705), total STAT3, pSTAT5 
(Y694/Y699), total STAT5, COX-2, Cyclin D1, and Cyclin D2 which were all 
acquired  from Santa Cruz Biotech (Santa Cruz, CA) at 4ºC overnight and 
secondary antibodies (Santa Cruz Biotech, Santa Cruz, CA). conjugated to 
peroxidase for 1 h at room temperature. Blots were then developed with an ECL 
detection system. Densitometric analysis was then performed using ImageJ 1.x 
software [134]. 
 
Animal model for FAP and CRC 
ApcMin/+ mice are a well-established and accepted model for studying FAP and 
CRC. The mice characteristically exhibit a germline nonsense mutation at codon 
850 of the APC gene that causes the spontaneous development of polyps, which 





Enterotoxigenic Bacteriodes fragilis (ETBF) exists asymptomatically in 12.4% of 
individuals overall and in 27% of individuals with diarrhea symptoms [135]. 
Furthermore, presence of ETBF in the gut is a well-known global cause of 
diarrheal disease that is accompanied by colitis in both humans and animals. The 
pathogenicity associated with ETBF is due to the secretion of a 20 kDa zinc-
dependent metalloprotease toxin, B. fragilis toxin (BFT), which binds to colonic 
epithelial cells and leads to the cleavage of the tumor suppressor protein, E-
cadherin, and the secretion of interleukin-8 [136]. Overall, this process leads to 
the stimulation of proliferation and migration of human colon cancer cells  [137]. 
BFT has also been shown to induce pro-inflammatory cytokine secretion by 
further activating the NFƘB pathway [137]. 
 
In vivo FAP and CRC studies 
Animal experiments were performed in agreement with an approved protocol by 
the Institutional Animal Care and Use Committee at the University of Louisville. 
Breeding colonies were established by Dr. Nejat K. Egilmez’s lab [138] at the 
University of Louisville using C57BL/6J Min/+ (ApcMin/+) mice that were originally 
attained from Jackson Laboratories (Bar Harbour, ME). Mice were genotyped for 
the APC mutation using PCR according to the protocol established by Jackson 
Laboratories. Mice were fed a standard chow diet. Animals received diet and 
water ad libitum and were maintained on a standard light/dark cycle for the 
duration of the study. For the FAP study, treatments began when animals were 
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8-9 weeks old. Male (n=4) and female (n=4) ApcMin/+ mice were  administered by 
oral gavage 40 mg/kg Anthos or vehicle control. Animals were treated 3 times 
per week for 5 weeks. Animals were euthanized at 13-14 weeks. Following 
fixation of intestines using formalin, intestinal polyps were counted using a 
microscope (Leica EZ4, Wetzlar, Germany) by four different experienced 
individuals after blinding the samples.  
 
Two CRC studies were performed to test the impact of the Anthos on tumor 
number. At 5-6 weeks of age, animals were administered antibiotic. Four days 
later the animals were administered ETBF to promote tumorigenesis and one 
week following ETBF inoculation, animals began their respective treatment 
regimen. In the first study male ApcMin/+ mice were administered by gavage 20 
mg/kg Anthos or vehicle control. Animals were treated 5 times a week for 4 
weeks. Animals were culled in the fed state at 12 weeks and colon tumors were 
counted. For the second study female ApcMin/+ mice were administered by 
gavage 40 mg/kg Anthos or vehicle control. Animals were treated 3 times a week 
for 4 weeks. Animals were culled in the fed state at 11-12 weeks and colon 
tumors were counted.  
 
 Data analysis 
Statistical analysis was performed using Graph Pad Prism statistical software 
version 4.03 (La Jolla, CA) and  RStudio software version 1.0.153 (Boston, MA) 
Lattice package [139, 140]. Test for normality, F-test for equal variance, and 
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appropriate t-test were used for both animal studies and for analysis of western 
blot results. IC50 values were determined using CalcuSyn software version 2.1 
(Biosoft, Cambridge, England). Heat maps were constructed using RStudio 




Anti-proliferative effects of Anthos on colon cancer cells but not normal 
colon cells 
Previous work within our laboratory has shown that anthocyanidins are more 
potent than their respective anthocyanins  [133]. However, prior to pursuing work 
with Anthos, we first compared antiproliferative activity of anthocyanidins and 
anthocyanins by using two individual anthocyanins (anthocyanins delphinidin 3,5-
diglucoside, cyanidin 3,5-diglucoside and cyanidin 3-glucoside) with their 
respective anthocyanidins (delphinidin and cyanidin) in HCT-116 colon cancer 
cells. As shown in Figure 6, a clear benefit is derived for antiproliferative activity 
from the cleavage of the sugar moiety from the anthocyanin parent compound. 
This is best demonstrated by the reduction in the IC50 shown for delphinidin 
which yielded >6-fold reduction when the sugar moiety was absent. A reduction 
was also observed when comparing cyanidin versus cyanidin 3-glucoside, and 
cyanidin 3,5-diglucoside, with 2- and nearly 5-fold reductions, respectively 







Figure 5. Representative chromatogram of C18-enriched bilberry-derived 
Anthos: HPLC profile of bilberry-derived anthocyanidin native mixture including 
delphinidin (Dp), cyanidin (Cy), petunidin (Pt), peonidin (Pe), and malvidin (Mv). 


























Figure 6. Antiproliferative activity of select  anthocyanidins and their 
anthocyanin counterparts against colon cancer cell line HCT-116: Colon 
cancer  HCT 116 cells were treated with various concentrations of the individual 
anthocyanidins, cyanidin (Cy) or delphinidin (Dp) and their anthocyanin 
counterparts cyanidin 3-glucoside (C3G), cyanidin 3,5-diglucoside (C3DG) or 
delphinidin 3,5-diglucoside (D3DG), respectively for 72 h and the effect on cell 



















Figure 1: Antiproliferative action of 





























Figure 7. Antiproliferative activity of Anthos against colon normal and 
cancer cells in vitro: Colon normal cells, CCD-18Co and colon cancer cells, 
HCT-116 and HT-29 were treated with various concentrations of Anthos for 72 h 
and the effect on cell growth inhibition was assessed using an MTT assay. Data 




























CCD-18Co 1050 - 
HCT116 75 14 
HT-29 124 9 
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Once anthocyanidins were confirmed to yield greater antiproliferative properties 
than their parent anthocyanins, we assessed the antiproliferative properties of a 
native mixture of Anthos found in bilberries and whether this native mixture 
showed any in vitro toxicity toward normal colon CCD-18Co cells (Figure 7). 
Tabulated selectivity index (SI) values (Table 1) of 14 and 9 clearly show that 
Anthos selectively targets colon cancer cells (HCT-116 and HT-29) over the 
normal cells (CCD-18Co).  It should also be highlighted that these values are well 
above the recommended minimal SI value of 3 that is commonly used to 
determine whether a drug selectively targets cancer cells over normal cells.  
 
Impact of Anthos on polyp development in ApcMin/+ mice FAP model 
A wide variety of plant-derived compounds, including but not limited to 
compounds such as curcumin, epigallocatechin gallate and anthocyanins have 
been shown to have chemopreventive properties [129].  However, large doses 
have been a hallmark prerequisite for their efficacy in vivo [129]. Therefore, in 
order to test whether Anthos is both efficacious and translatable for the required 
dose to elicit such properties, we investigated the effect of the Anthos on 
intestinal polyp number utilizing  ApcMin/+ mice. Both male and female mice (n=4 
per group) were treated with 40 mg/kg Anthos three times per week 
(approximating 17 mg/kg/day)  for four weeks by oral gavage. Results from the 
study (Figure 8a) showed a greater than 2-fold overall reduction in intestinal 
polyps in Anthos versus vehicle control. The overall results in both male and 








Figure 8. Anti-polyp and anti-tumor activities of Anthos against intestinal 
polyps and colon tumors: a) ApcMin/+  mice were treated via oral gavage with 
Anthos three times a week (40 mg/kg bw) or vehicle control. Data represent the 

































Figure 4: A) Effect of bilberry-derived anthos on tumor formation in ETBF 
treated female and male APCmin/+ mice. Animals received anthos orally 3x 
week for 5 weeks. B) Image highlighting the differences in tumor size 








Anthos versus control P=0.02 and female Anthos versus control P=0.004. b) 
ApcMin/+ mice inoculated with ETBF were treated via oral gavage with Anthos 
three times per week (40 mg/kg bw), five times per week (20 mg/kg bw), or 
vehicle control. Data represent the distribution of animal tumor counts by gender, 
with the average noted. Male and female Anthos versus control P<0.001. c) 
Representative images of colons taken from control versus Anthos-treated 


















statistically significant (P=0.02 and P=0.004, respectively). Interestingly, when 
the data was stratified by sex, it was noted that the effect of Anthos treatments 
was somewhat enhanced in female mice which showed 3.1 fold reductions in 
polyp numbers (P=0.004) as compared to the 1.8 fold reduction (P=0.02) found 
within males. 
 
Impact of Anthos on colon tumor development in ETBF ApcMin/+ mice CRC 
model 
Previous work within our group has shown that Anthos decreases tumor burden 
in lung and ovarian cancer models [142] [78] . However, no work has been 
reported to assess the impact of bilberry-derived Anthos against either FAP, 
colorectal cancer or bacterially-induced cancers. Therefore, following the 
completion of in vitro testing of Anthos in both APC wild-type and APC mutant 
cell lines, we investigated whether Anthos treatment would impact colon tumor in 
a bacterially-driven ApcMin/+  colorectal cancer mouse model. In these studies, 
mice which were treated with Anthos at either 20 mg/kg Anthos 5 times per week 
(i.e. 14 mg/kg/day) or 40 mg/kg 3 times per week (i.e. 17 mg/kg/day) for 4 weeks 
by oral gavage. Results show an average reduction of 2.6 fold in the number of 
colorectal tumors in Anthos-treated mice compared with control (Figure 8b and 








Figure 9.  Changes in Src and EGFR phosphorylation after treatment with 
Anthos: Colon cancer cell line HT-29 was treated with various concentrations of 
Anthos overnight and the effect on phosphorylation of Src (Y418) and EGFR 
(Y1068) was assessed using western blot analysis and compared to total EGFR 
and β-actin loading control. Densitometry values listed are the ratio of each dose 
to the vehicle control for the phospho-protein/total protein, both corrected for β-
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1 0.86 0.67 0.30
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Insights into Anthos mechanism of action 
To understand Anthos mechanism of action we focused on the Src and EGFR-
related pathways. Our preliminary in vitro work with lysates prepared from 
Anthos-treated APC mutant HT-29 cells showed that Anthos treatment led to a 
dose-dependent decrease in the phosphorylation status of EGFR (Y1068) and 
Src (Y418) (Figure 9). With these promising in vitro findings we next sought to 
determine the influence of Anthos treatment on the Src and EGFR-related 
pathways in an ETBF-treated ApcMin/+ mouse model which has been reported to 
have increased  EGFR activity and c-Src expression in the adenoma and 
intestinal enterocyte tissue. Results from our analysis (Figure 9) of the 
phosphorylation status of the tyrosine kinase, Src at position Y418 showed a 
significant decrease in phosphorylation in Anthos-treated animals compared to 
control animals. The phosphorylation status of transphosphorylation site Y845 of 
the receptor tyrosine kinase (RTK), EGFR, a site noted for its activation by Src 
was also significantly decreased in adjacent normal and colon tumor samples 
taken from Anthos–treated animals over control animals. The transcription factor, 
STAT5a/b, which is immediately downstream of EGFR Y845, also showed a 
significant decrease in phosphorylation at tyrosine positions 694 and 699 in both 
adjacent normal and tumor tissue samples from Anthos treated animals. The 
ultimate expression of the downstream targets cyclin D1, cyclin D2 and COX-2 
were also significantly downregulated in the Anthos group for both adjacent 
normal and tumor tissue samples (Figures 10-12). Interestingly, significant 





Figure 10. In vivo changes in Src and EGFR pathways following treatment 
with Anthos: changes in the phosphorylation and expression of Src and EGFR 
along with corresponding downstream pathway targets including STAT3, STAT5, 
cyclin D1, cyclin D2, and COX-2 in a) adjacent normal  and b) tumor colon tissue 
taken from ETBF-inoculated ApcMin/+  mice after treatment with Anthos or vehicle 
control as assessed using western blot analysis with β-actin loading control. 





































Figure 11. Representative heatmap for in vivo changes in Src and EGFR 
pathways following treatment with Anthos:  representative heat map legend 
depicts the average fold change and significance level in either phosphorylation 
status or expression levels between Anthos treated and vehicle control animals 
within either adjacent normal (n=3) or tumor colon tissue (n=3).  
 
Significance level attained 
for comparison of average 
Anthos to control sample 
expression/phosphorylation  
P < 0.05 * 
 P < 0.01 ** 
    P < 0.001 *** 




























Table 1. Raw densitometry values calculated for Src/EGFR pathway 
western blot analysis 
Target 
Adjacent Normal Tumor 
Control Anthos Fold change Control Anthos Fold change 
Src 6883 7922 1 9558 8474 -1 
Src (Y418) 20688 4816 -4 20516 6259 -3 
EGFR 18661 20531 1 18388 20599 1 
pEGFR (Y845) 18141 5950 -3 17230 8659 -2 
pEGFR (Y1068) 19771 17469 -1 25990 12493 -2 
pEGFR (Y1173) 21496 20029 -1 16854 10731 -2 
pSTAT3 15938 11067 -1 25354 5274 -5 
STAT3 5088 7000 1 10291 8208 -1 
pSTAT5 19969 3436 -6 25057 6779 -4 
Cyclin D1 22846 7075 -3 27696 14658 -2 
Cyclin D2 21036 6480 -3 15580 3503 -4 











Figure 12. Pathway involving modulation of Src and EGFR phosphorylation 
status and downstream targets: the pathway deduced is based upon results 
from western blot analysis for adjacent normal and tumor tissue samples and is a 









































EGFR Y1068 and Y1173 were noted in the tumor but not the adjacent normal 
colon tissue of Anthos treated compared to control animals. This difference 
between adjacent normal and tumor tissue was also noted in the phosphorylation 
status of the immediate downstream protein STAT3, with a significant decrease 
in the phosphorylation at Y705 observed only in the tumor tissue and not the 
adjacent normal tissue in Anthos treated animals. A significant decrease in the 
levels of total EGFR, which was factored into the determination of 




Although much progress has been achieved in the treatment of CRC, it remains 
the third leading cause of cancer-related death in the U.S. Furthermore, FAP 
remains an orphan disease with the only viable treatment option being surgical 
resection of the colon. Even after this drastic procedure, individuals with FAP are 
still at a greater risk for developing cancers of the small intestine. With the above 
factors in mind, the development of alternative prevention and treatment 
strategies for combating both FAP and CRC are of great importance and 
represent an unmet need.  
One particular class of plant bioactive compounds that have been studied for 
their health-promoting properties is that of the anthocyanins. This family of 
colored pigments is particularly promising given its long history as a dietary 
constituent for many humans. However, anthocyanins, when taken in their native 
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form are often plagued by issues with their limited bioavailability and stability, 
which effectively limit their translation into a clinically-viable option due to the 
large doses that would need to be consumed in order to elicit therapeutic 
efficacy. With this in mind, the focus of this study has been to utilize the Anthos, 
which we have previously shown to be more active than the native anthocyanin 
counterpart in A549 lung cancer cells [133]. This relationship is also valid in colon 
cancer with delphinidin, and cyanidin yielding greater potency than their 3-
monoglucoside and 3,5-diglucoside anthocyanin counterparts. These results are 
not surprising considering that anthocyanidins are somewhat more lipophilic due 
to their higher partition coefficients than their anthocyanin counterparts. For 
example, the anthocyanin, cyanidin 3,5-O-diglucoside has an octanol to water 
(KOW) partition coefficient of 0.21 as opposed to its anthocyanidin counterpart, 
cyanidin which has a partition coefficient of 10.07 [143]. These higher partition 
coefficients enable anthocyanidins to be taken up passively by cells whereas 
anthocyanins are known to require active transport and thus may be limited in 
their transport efficiency/limitation [81].  
 
Anthos were not only more potent than their anthocyanin counterparts, but 
exhibited selectively toxicity towards colon cancer cells over the normal colon 
cells with SI values that were well above the recommended cutoff for lack of 
toxicity.  We had previously shown that Anthos were non-toxic in wild-type mice 
[144]. Furthermore, work with anthocyanins derived from blueberry, black currant 
as well as elderberry showed no toxicity when administered to rats (20 
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mg/kg/day), mice (25 mg/kg/day), or guinea pigs or rats (>3 g/day for 15 days or 
90 days) [145].  
 
Given the lack of more favorable/less invasive treatment options for FAP and the 
severity and ultimate lethality of the disease at early ages, there is a great need 
for developing alternative preventative treatment options. With this unmet  need, 
the potential application of Anthos to the prevention of FAP is a key possibility 
based on our in vivo findings indicating significant decreases in intestinal polyp 
number with Anthos intervention in ApcMin/+ mouse model.  In addition to the 
promising results attained with the chemoprevention in the FAP study, Anthos 
exhibited significant anti-tumor activity against ETBF induced colorectal tumors in 
the ApcMin/+ mouse model.    
 
 ETBF, a subtype of B. fragilis that secrets the metalloprotease enterotoxin B. 
Fragilis toxin (BFT), is associated with diarrheal disease in both humans and 
animals as well as active inflammatory bowel disease. A study looking at the 
prevalence of ETBF found that 26.8% of individuals with diarrhea and 12.4% of 
individuals without diarrhea had stool samples that were positive for the presence 
of ETBF [135]. Furthermore, a recent study looking at the bacterial composition 
in individuals with FAP compared to normal controls found that the colonic 
mucosa of individuals with FAP were highly enriched with genes for the toxin, 
BFT, that is secreted by the ETBF bacteria [28]. In view of our encouraging 
findings, it is presumable that use of Anthos in human inflammatory bowel 
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conditions and colorectal tumors associated with ETBF and FAP could be of 
great benefit. 
 
We have previously shown that Anthos favorably modulate targets such as β-
catenin, cyclin D1, cyclin B1, pERK, VEGF proteins, c-myc and MMP9 in lung 
cancer H1299 cells [25]. Furthermore, anthocyanin substitution patterns were 
found to lead to different cellular signaling cascades effects [36]. For instance, 
only malvidin which features methoxy groups at the 3’ and 5’ positions of the B-
ring lead to inhibition of cAMP-specific phosphodiesterases (PDEs) whereas, 
cyanidin and delphinidin were shown to inhibit EGFR in human vulva carcinoma 
A431 cells [36]. In this report, we deduced mechanistic work utilizing APC mutant 
colon cancer cells and adjacent normal and colon tumor tissue samples from 
ETBF ApcMin/+ mouse model treated with Anthos. It was previously shown that 
APC deficiency was associated with an increase in EGFR activity and c-Src 
expression in ApcMin/+ mouse adenomas and intestinal enterocytes [146]. 
Furthermore, In addition to increasing the secretion of chloride and permeability 
of intestinal epithelial cells, BFT also activates STAT3 and TH17 responses and 
leads to increased COX-2 [147]. However, no work had been conducted to 
assess the impact of Anthos or anthocyanins on Src in any cancer model or 
Anthos on EGFR in a colorectal cancer model.  In vitro work using the APC 
mutant HT-29  colon cancer cells showed a clear dose-dependent decrease in 
the phosphorylation status of Src (Y418) and EGFR (Y1068). Results from our 
survey of the Src and EGFR-related pathways show a significant decrease in Src 
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phosphorylation (Y418), EGFR phosphorylation (Y845) and the downstream 
mediator STAT5a/b (Y694 and Y699), both in adjacent normal and colon tumor 
tissue taken from ETBF treated ApcMin/+ mice that received Anthos treatment. 
Furthermore, phosphorylation status of EGFR at Y1068 and Y1173 along with 
the downstream mediator STAT3 (Y705) was shown to decrease in tumor tissue 
in Anthos treated mice. Key regulators of cell cycle progression and 
inflammation, including Cyclin D1, Cyclin D2 and COX-2, were shown to be 
favorably modulated by Anthos, with the most dramatic reductions in expression 
observed in tumor tissue samples. Overexpression of COX-2 has been noted in 
colon tumor tissue and plays a role in the pathogenesis of FAP, ETBF and 
ultimately colon cancer [148, 149]. Overall, these findings provide novel 
mechanistic insight into the method by which Anthos achieve both 
chemopreventive and therapeutic effects against a highly relevant bacterially-
driven colon cancer model.  
 
In summary, our data provide compelling evidence for the use of a bilberry 
Anthos against FAP and CRC. Anthos were shown to yield greater potency and 
efficacy than their counterpart anthocyanins and no toxicity toward normal colon 
cells in vitro. Furthermore, in vivo anti-polyp and anti-tumor efficacy along with 
corresponding mechanistic insight suggest that Anthos lead to a potent decrease 
in the phosphorylation status of Src, EGFR, STAT5, STAT3 and expression of 
key markers for proliferation and inflammation including cyclin D1, cyclin D2, and 
63 
 
COX-2. Overall, results from this study offer an exciting possibility for potential 
treatments with berry Anthos for FAP and CRC in the future. 
 
Abbreviations  
CRC: colorectal cancer, Anthos: native anthocyanidins mixture from billberry, 
FAP: familial adenomatous polyposis, APC: adenomatous polyposis coli, COX-2: 
cyclo-oxygenase-2, Cy: cyanidin, Dp: delphinidin, Pt: petunidin, Mv: malvidin, Pe: 
peonidin, HPLC: high performance liquid chromatography, PDA: photodiode 
array detector, UV: ultraviolet, ETBF: enterotoxigenic Bacteriodes fragilis, BFT: 

















THE ROLE OF ANTHOCYANIDINS IN RE-EQUILIBRATING METABOLIC SHIFTS INDUCED BY 
DYSBIOSIS OF THE GUT MICROBIOME AND THE UBIQUITOUS ENVIRONMENTAL 
CARCINOGEN, BENZO[a]PYRENE 
Colorectal cancer (CRC)  
Although much progress has been made in the diagnosis and treatment of 
cancer over the last thirty years, CRC remains as a looming threat on the 
horizon. For instance, although the incidence of CRC  has been trending 
downward since the mid to late 1980s for individuals 55 years or older, a recent 
study has found a rather disconcerting uptick in the CRC incidence for individuals 
below 55 years old [12].   According to the CDC, the third most common form of 
cancer in the US is CRC. Furthermore, CRC is the third leading form attributed to 
cancer-related deaths each year. In fact, according to the American Cancer 
Society, it is estimated that 140,250 individuals will be diagnosed and 50,630 will 
die from CRC in the US in 2018 alone. Epidemiological studies suggest that 
lifestyles with diets rich in fat, smoking, and alcohol consumption as well as 
exposure to environmental pollutants and dysbiosis of gut microbiota increase 
the risk of developing CRC [3, 150]. Much progress has been made in combating 
the disease due to advancements made in early detection of CRC. However, 
options for chemoprevention from environmental insult and an understanding of 
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how such treatments could alter the dialogue between one’s microbiome and 
environmental toxins have yet to be achieved. 
Factors in the development of CRC 
Environmental factors in CRC  
Environmental factors such as air pollution, cigarette smoke, and dietary 
contamination have been epidemiologically and mechanistically linked to an 
increased risk of CRC [151-153]. One particular class of environmental pollutants 
that is especially pervasive is polycyclic aromatic hydrocarbons (PAHs). One of 
the most ubiquitous members of this family is benzo[a]pyrene (B[a]P) which is 
found in cigarette smoke, as a contaminant in many foods, car exhaust fumes, 
wood burning and coal tar. In order initiate the carcinogenic process, B[a]P 
undergoes bioactivation by enzymes, such as the cytochrome P450 (CYP) 1A1 
and/or 1B1 and microsomal epoxide hydrolase (mEH) (1 , 4 , 5 ), resulting in the 
formation of the ultimate carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide 
(BPDE). Various enzymes including members of the glutathione s-transferase 
(GST), uridine 5'-diphospho-glucuronosyltransferase (UGT) and sulfotransferase 
(SULT) families are involved in the detoxification of the intermediates along this 
bioactivation pathway (Figure 13). The metabolites of B[a]P are classified as 
group 1 carcinogens by the International Agency for Research on Cancer (IARC). 
BPDE intercalates DNA and ultimately covalently binds with guanine bases. This 














mutations. BPDE has also been found to target p53 thereby altering the tumor  
suppression of cells which may ultimately lead to cancer [23]. Interestingly, 
research that measures all of the exposures of an individual in a lifetime and how 
those exposures relate to health referred to as “exposome” has found that 
exposure to B[a]P leads to the enhanced susceptibility of macrophage 
membranes to bacterial infection and ultimately may lead to immunosuppression 
[154]. Although one of the first carcinogens to be studied, B[a]P remains a 
continued threat due to its widespread presence in the environment. Given the 
continued relevance of B[a]P, work looking at how this and its metabolites 
interact with endogenous factors such as the gut microbiome is of  high 
importance in addressing the management of several diseases including colon 
cancer. 
Bacterial carcinogens 
In addition to traditional carcinogens such as B[a]P, recent research has begun 
to uncover the importance of the gut microbiome in the development of CRC. 
Research has shown that imbalances in the intestinal microbiota lead to both an 
increase in inflammatory conditions as well as an increased production of 
carcinogenic metabolites, which may ultimately lead to neoplasia. Several 
bacteria have been associated with increased risk of developing CRC including: 
S. gallolyticus, H. pylori, virulent forms of Escherichia coli (E. coli), 
Fusobacterium nucleatum (F. nucleatum), Salmonella enterica (S. enterica) and 
enterotoxigenic B. fragilis [155]. Furthermore, a bidirectional dialogue has been 
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found to exist between the gut microbiome and environmental chemicals, with 
bacteria metabolizing the pollutants contributing to host toxicity and the 
contaminants altering the composition of gut microbiota [150]. This dynamic 
interaction between the host microbiome and environmental carcinogens is 
becoming ever more prevalent and relevant in the modern era. Furthermore, little 
is known regarding the impact that gut bacteria such as ETBF has on the 
expression of phase I/II enzymes. With this in mind, identifying a 
chemopreventive method to combat this omnipresent insult is of great 
importance. 
Anthos background 
Anthos role in detoxification 
Several plant bioactives have been an invaluable source of medicines for 
humans. The family of plant pigments, known as the anthocyanins, have been 
identified with a variety of health benefits including chemopreventive and 
therapeutic effects due to their roles as anti-inflammatory, antioxidant agents and 
modulators of cytochrome P450 enzymes, CYP1A1 and CYP1B1 in mammary 
tissue [94, 131]. Found in dark-colored vegetables, fruits, grains and flowers, 
anthocyanins provide the characteristic red, purple and blue hues. Anthocyanins 
are, in part, converted to anthocyanidins (Anthos), the aglycone moieties, and, in 
fact, have higher antiproliferative and anti-inflammatory activities than the 




The berry bioactive, Anthos present a promising chemopreventive option for 
individuals to avoid developing CRC. Berries were shown to reduce the oral 
dysplasia and carcinoma-in-situ by approximately 50% in animals previously 
treated with a mixture of the cigarette smoke carcinogens, B[a]P and NNK [156]. 
Previous work from our laboratory against breast and lung cancer has shown that 
Anthos possess chemopreventive as well as therapeutic effects due to their roles 
as anti-inflammatory, antioxidant agents and modulators of CYP1A1 and 
CYP1B1 [157]. We demonstrated that intervention with the anthocyanidin, 
delphinidin favorably modulated the underlying mechanisms of potent PAHs 
[158]. It should also be noted that work with both anthocyanins and Anthos 
suggest that these compounds do not influence the expression or activity of key 
enzymes involved in drug metabolism including CYP3A4, CYP2A6, CYP2B6, or 
CYP2C9 [159]. Furthermore, although work has been conducted to research the 
impact of anthocyanins on CRC [97, 160], no research had previously been 
conducted to study the impact of Anthos or ETBF bacteria on alterations in phase 
I and II enzyme expression.  
With this in mind, the aim of this series of studies was to assess how treatment 
with a native mixture of anthocyanidins derived from bilberry (Anthos) and an 
exosomally-delivered preparation of Anthos (ExoAnthos) influences proliferation 
and modulation of expression of key phase I and II enzymes both in vitro and in a 
bacterially-induced in vivo model of colorectal cancer. Furthermore, the influence 





Materials and Methods 
Chemicals 
B[a]P was handled carefully with all safety procedures as it is a highly 
carcinogenic and hazardous chemical. B[a]P (B-1760, St. Louis, MO) was  
purchased from Sigma-Aldrich. 
Isolation of bilberry-derived Anthos 
The native bilberry Anthos mixture that was generously provided by 3P 
Biotechnologies (Louisville, KY) was further enriched using C18 Sep-Pak 
cartridges (Waters, Milford, MA) and eluted in acidified (0.1% HCl) ethanol. The 
enriched extract was then dried using a Savant SC210A Speed-Vac 
(ThermoFisher Scientific, Waltham, MA) and stored at -20 °C. Purity was verified 
using HPLC-PDA-UV. Briefly, 15 µl samples were analyzed using a Shimadzu 
Premier C18 reverse-phase column (250x4.6 mm i.d., 5 µm). Mobile phase A 
was composed of water: formic acid: acetonitrile (87:10:3) and mobile phase B 
was composed of water: formic acid: acetonitrile (40:10:50). The flow rate was 
0.6 ml/min and the gradient condition was 0-5 min 5% B; 5-15 min 15% B; 15-20 
min 25% B; 20-30 min 35% B; 30-40 min 45% B; 40-45 min 100% B; 45-50 min 
5% B. Detection of Anthos was at 520 nm by PDA-UV and total Anthos 
concentration was calculated using a standard curve. The reference compounds 
were purchased from Cayman Chemical Company (Ann Arbor, MI). The HPLC 
analysis of the Anthos was conducted by Mr. Jeyaprakash Jeyabalan, a 
Research Scientist in our laboratory. 
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Isolation of milk derived exosomes 
Exosomes from cow colostrum were isolated  using differential centrifugation as  
described by Munagala et al., [115], and were generously provided by 3P 
Biotechnologies (Louisville, KY).   
Protein determination  
Protein estimation for exosomal preparations was assessed using a bicinchoninic 
acid (BCA) assay (Thermo Scientific, Rockford, IL).  In order to determine protein 
concentration, diluted exosomal preparations were compared, in triplicate, to a 
serially diluted bovine serum albumin (BSA) standard curve.  
ExoAnthos drug loading 
Anthos was loaded onto exosomes by mixing Anthos (dissolved in ethanol and 
water) with the exosomes suspension in a 1:5 (Anthos:Exosomal protein, w/w) 
ratio at room temperature (22 ºC). Unbound Anthos and any co-agulated 
exosomes were  removed by low speed centrifugation (10,000×g for 10 min). The 
exosomes that were loaded with Anthos were then collected by 
ultracentrifugation (135,000 xg for 1.5 h). The pellet was then suspended in PBS 
and passed through a 0.22 µ filter and stored at -80 ºC. The percent loading was 
determined using solvent extraction.  
Analysis of drug loading 
In order to determine the load of Anthos in the ExoAnthos formulation, the protein 
and Anthos concentrations were measured. Briefly, a 50 µl aliquot of ExoAnthos 
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formulation was mixed with 950 µl of acidified ethanol (0.1% HCl). The 
precipitated proteins were separated by centrifugation (10,000 x g for 10 
minutes). The drug contained in the supernatant was then analyzed using a 
SpectraMax M2 spectrometer (Molecular Devices, Sunnyvale, CA). Anthos were 
detected at 520 nm and total Anthos concentration was calculated using a 
standard curve. Reference anthocyanidins were acquired from Chromadex 
(Irvine, CA). Anthos concentrations were confirmed via HPLC-PDA. The pelleted 
exosomal proteins were determined by the BCA method described above. The 
percent drug load when then calculated by dividing the amount of Anthos by 
exosomal proteins x 100 [115]. Equal loading of individual Anthos was confirmed 
using HPLC-DAD.  
Characterization of Exosomes and ExoAnthos 
The size of colostrum-derived exosomes and ExoAnthos, which were diluted in 
PBS to 1 mg/ml, were determined using a Zetasizer (Malvern Instruments Ltd, 
Malvern, Worcestershire, UK). Colostrum  exosome and ExoAnthos morphology 
were determined by atomic force microscopy (AFM). Briefly, exosomes and 
ExoAnthos were diluted with deionized water to 10 µg/ml. A 2 µl aliquot of each 
sample was then placed on a silica wafer and air dried for 30 min. Images were 
captured using an Asylum MF-3D AFM (Oxford Instruments, Goleta, CA)  in 
tapping mode using aluminum-coated silicon probes.  The amplitude, 
topographic height and phase retraces were imaged with a fixed force (<1nN) at 
a scanning rate of 1 Hz. Images were processed using IGOR software. The AFM 
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analysis was performed by Mr. Jeyaprakash Jeyabalan, a Research Scientist in 
our laboratory. 
Cells, culture conditions and treatments 
The APC wild-type HCT 116 (ATCC® CCL-247™) colon cancer cell line and 
CCD-18Co (ATCC® CRL-1459™) normal colon cells were acquired from 
American Type Culture Collection (Manassas, VA). The APC mutant colon 
cancer cell line HT-29 (ATCC® HTB-38D™) was a kind gift from Dr. Nobuyuki 
Matoba (University of Louisville). HCT-116 and HT-29 cells were maintained in 
McCoy’s 5A medium (Gibco, Grand Island, NY) supplemented with 10% FBS, 
100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere 
containing 5% CO2 at 37°C. Cells were pre-treated with Anthos (25, 50, 100, 200 
µM) for 24 h and co-treated with Anthos (25, 50, 100, 200 µM) and B[a]P (20 µM) 
for 24 h.  
 
Measurement of cell viability 
The cytotoxicity of bilberry Anthos in colon cancer cell lines was assessed by 
enzymatic reduction of the tetrazolium dye MTT. Briefly, 3.0 x103 cells/well were 
grown in a 96-well tissue culture plates and were then exposed to varying 
concentrations of bilberry Anthos or vehicle control 24 hours after seeding. After 
72 h treatment, cells were incubated with 5 mg/ml MTT reagent for 2 h. Resulting 
formazan crystals were subsequently solubilized in DMSO and 
spectrophotometrically measured at 570 nm (Bio-rad, Philadelphia, PA). IC50 
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values were then determined using Calcysyn software version 2.1 (Biosoft, 
Cambridge, England).   
 
Western-blot analysis  
For western-blot analysis, 40 µg of protein from in vitro and in vivo tissue lysates 
was resolved using SDS-polyacrylamide gel electrophoresis and 
electrotransferred to polyvinylidene difluoride membranes by semi-dry transfer 
(Biorad Trans-blot SD, Hercules, CA). Blots were blocked with 4% dry powder 
milk or BSA for 1 h and then incubated with primary antibodies β-actin, UGT1A6, 
SULT1, GSTM1, GSTM2, CYP1A1, CYP1B1, PXR, Nrf2, AhR, AhRR, and 
ARNT1 which were all acquired  from Santa Cruz Biotech (Santa Cruz, CA) at 
4ºC overnight and secondary antibodies (Santa Cruz Biotech, Santa Cruz, CA). 
conjugated to peroxidase for 1 h at room temperature. Blots were then developed 
with an ECL detection system. Densitometric analysis was then performed using 
ImageJ 1.x software [134]. 
 
Animal model for CRC 
ApcMin/+ mice are a well established and accepted model for studying FAP and 
CRC. The mice characteristically exhibit a germline nonsense mutation at codon 
850 of the APC gene that causes the spontaneous development of polyps, which 
predominantly occur in the small intestine by the age of 10-12 weeks.  
Enterotoxigenic Bacteriodes fragilis (ETBF) is a highly relevant model for 
development of CRC due to its contribution to both familial and sporadic forms of 
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cancer [28, 135]. ETBF exists asymptomatically in 12.4% of individuals overall 
and in 27% of individuals with diarrhea symptoms [135]. Furthermore, presence 
of  ETBF in the gut is a well known as a global cause of diarrheal disease that is 
accompanied by colitis in both humans and animals. The pathogenicity 
associated with ETBF is due to the secretion of a 20 kDa zinc-dependent 
metalloprotease toxin, B. fragilis toxin (BFT), which binds to colonic epithelial 
cells and leads to the cleavage of the tumor suppressor protein, E-cadherin, and 
the secretion of interleukin-8 [136]. Overall, this process leads to the stimulation 
of proliferation and migration of human colon cancer cells  [137]. It should also be 
noted that BFT has also been shown to induce pro-inflammatory cytokine 
secretion by further activating the NFƘB pathway [137]. 
 
In vivo CRC studies 
Animal experiments were performed in agreement with an approved protocol by 
the Institutional Animal Care and Use Committee at the University of Louisville. 
Breeding colonies were established in collaboration with  Dr. Nejat K. Egilmez’s 
lab [138] at the University of Louisville using C57BL/6J Min/+ (ApcMin/+) mice that 
were originally attained from Jackson Laboratories (Bar Harbour, ME). Mice were 
genotyped for the APC mutation using PCR according to the protocol established 
by Jackson Laboratories. Mice were fed a standard chow diet and received water 
ad libitum and were maintained on a standard light/dark cycle for the duration of 
the study. At 5-6 weeks of age, animals were administered antibiotic. Four days 
later the animals were administered ETBF to promote tumorigenesis and one 
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week following ETBF inoculation, animals began their respective treatment 
regimen. Male and female ApcMin/+ mice were orally administered (by gavage) an 
average of 8 mg/kg/day Anthos, 8 mg/kg/day ExoAnthos or vehicle control for 4 
weeks. Animals were culled in the fed state at 12 weeks, colon tumors were 
counted and tissues were harvested.  
 
Data analysis 
Statistical analysis was performed using Graph Pad Prism statistical software 
version 4.03 (La Jolla, CA) and  RStudio software version 1.0.153 (Boston, MA) 
Lattice package [139, 140]. Test for normality, F-test for equal variance, and 
appropriate t-test were used for both animal studies and for analysis of western 
blot results. One way ANOVA was used for assessing the significance of mean 
differences across the various treatments for western data.  IC50 values were 
determined using CalcuSyn software version 2.1 (Biosoft, Cambridge, England). 
Heat maps were constructed using RStudio software version 1.0.153 (Boston, 
MA)  gplot package [140, 141]. 
 
Results 
Anti-proliferative effects of Anthos and ExoAnthos on colon cancer cells 
but not normal colon cells 
Previous work from our laboratory has shown that exosomal formulation yielded 
enhanced  therapeutic potency and efficacy for drugs such as paclitaxel, 
celastrol, curcumin and Anthos against lung cancer due to increased stability and 
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bioavailability of these compounds [115-117, 142]. Prior to carrying out our in 
vivo work, we first determined the impact of ExoAnthos, exosomal vehicle (Figure 
14) and Anthos treatment on proliferation of HCT-116 and HT-29 colon cancer 
cell lines and CCD-18Co normal colon cells (Figure 15). Results from these 
studies showed a clear increase in the anti-proliferative properties of Anthos 
against colon cancer cells, with 4-16-fold decreases in the IC50 values of 
ExoAnthos as compared to the free Anthos (Figure 15). One can posit that the 
improved anti-proliferative effects of the ExoAnthos formulation over Anthos 
alone is most likely due to the increased cell uptake and stability in media of the 
ExoAnthos over Anthos. Part of the higher efficacy of ExoAnthos may be 
attributed to the intrinsic effect of the exosomes alone (Munagala et al. 2016, 
2017). 
 
In order to determine whether Anthos and ExoAnthos were selective toward 
colon cancer over normal colon cells in vitro we determined the selectivity index 
(SI) values for both HCT 116 and HT-29 colon cancer cells compared to normal 
colon CCD-18Co cells. The results (Table 2) showed not only that both Anthos 
and ExoAnthos were selective for colon cancer over normal colon cells, but that 
ExoAnthos enhanced this selectivity, with the greatest increase yielded in HT-29 
cells which went from an SI value of 9 for Anthos to 51 for ExoAnthos. Overall, 
these results confirm that Anthos and ExoAnthos do not show in vitro toxicity for 








Figure 14. Antiproliferative activity of Exosomes against colon normal cells 
and cancer cell lines: Colon normal cells CCD-18Co and colon cancer cell lines 
HCT-116 and HT-29 were treated with various concentrations of milk derived 
exosomes for 72 h and the effect on cell growth inhibition was assessed using an 
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Figure 15. Antiproliferative activity of Anthos and ExoAnthos against colon 
normal cells and cancer cells in vitro: Colon normal cells, CCD-18Co and 
colon cancer cells, HCT-116 and HT-29 were treated with various concentrations 
of bilberry-derived Anthos or ExoAnthos for 72 h and the effect on cell growth 






Table 2. Tabulated selectivity values for colon cancer and normal cells 





















Impact of Anthos treatment on tumor number in vivo 
As presented in chapter 2, Anthos led to a significant reduction in colon tumors in 
an ETBF Apcmin/+ mouse model when given at an average dose of 16 mg/kg. 
Given these promising results, we next sought to test our ExoAnthos formulation, 
which makes use of an exosomal nano delivery method to see if greater 
therapeutic effect could be achieved at lower doses due to enhanced stability 
and bioavailability of the Anthos. We have previously found that Exosomal 
delivery enabled us to achieve superior results for several drugs such as 
curcumin, celastrol and paclitaxel when given alone in vivo for breast and lung 
cancer [115-117, 144]. Results from the comparison of Anthos and ExoAnthos 
treatment showed that ExoAnthos lead to a similar reduction in colon tumor 
burden as Anthos alone, when given at the same dose (P=0.30). When 
compared to control, a significant reduction in colon tumors was noted in the 
ExoAnthos treated animals vs. exosome vehicle control (P=0.019) and Anthos 
treated animals vs. vehicle control (P=0.0025) when given at 8 mg/kg (Figure 
16). It should be noted that no significant difference was found between the 
tumor numbers in control vs. exosome alone treated animals (P=0.728).  
 
Impact of ETBF bacteria on phase I/II enzyme expression in colon/liver 
Prior to this study, no work had been completed assessing the impact of ETBF 
bacteria on the expression of phase I or II enzymes. However, there has been 




Figure 16.  Anti-tumor activities of Anthos and ExoAnthos against colon 
tumors. (A) Study overview, ApcMin/+  mice inoculated with ETBF were treated via 
oral gavage with Anthos or ExoAnthos three times a week (20 mg/kg bw) or 
vehicle controls. (B) Data represent the distribution of animal colon tumor counts, 
with the average noted. Anthos versus control (P=0.0025), control versus 
exosomes alone-treated animals (P=0.728), ExoAnthos treated animals versus 
exosomes vehicle control (P=0.019), Anthos versus ExoAnthos  (P=0.30). *** 
signifies P<0.001, ** signifies P<0.01, and * signifies P<0.05. 
B.













microbiome on the metabolism of drugs and environmental chemicals such as 
polybrominated diphenyl ethers (PBDEs)  [161].  Results from our investigation of 
the influence of ETBF bacteria on the expression of phase I and II enzymes in 
ApcMin/+ mice treated with the bacteria showed significant increases in the 
expression of the phase I enzymes CYP1A1 and CYP1B1. Additionally, a 
significant decrease in the expression of the phase II enzyme GSTM1 in normal 
colon tissue was also noted. In order to assess how ETBF bacteria influences the 
expression of these phase I and II enzymes we assessed the expression of AhR, 
AhRR, ARNT1, Nrf2, VDR and PXR in ApcMin/+ mice with and without ETBF 
treatment. Results from this survey (Figure 17) showed that mice treated with 
bacteria had highly significant decreases in the expression of the AhR repressor, 
AhRR. No significant changes in the expression of PXR, Nrf2, and VDR 
expression were noted in colon tissue samples taken from the mice that received 
bacteria. Liver samples taken from bacteria-treated mice also featured decreased 
expression of the phase II enzymes UGT1A6 and GSTM1 and increased 
expression of AhR when compared to ApcMin/+ mice that did not receive bacteria.  
 
Impact of Anthos treatment on phase I/II enzyme expression in vivo: 
colon/liver 
In chapter 2, we showed that Anthos treatment led to decreases in the 





Figure 17. In vivo changes in phase I and II enzyme expression and related 
xenobiotic sensing nuclear receptors in normal colon tissue following 
treatment with ETBF bacteria, bilberry-derived Anthos or ExoAnthos: changes 
in the expression of key phase I and II enzymes along with key nuclear receptors 
including CYP1A1, CYP1B1, GSTM1, SULT1, AhR, AhRR, ARNT1, Nrf2, PXR and 





treatment with bilberry-derived Anthos, ExoAnthos or vehicle control as assessed 
using western blot analysis compared to with Apc
Min/+  mice that received no 
























Figure 18. Representative heatmaps for In vivo changes in phase I and II 
enzyme expression and related xenobiotic sensing nuclear receptors. 
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 P < 0.01 ** 
    P < 0.001 *** 





Table 3. Raw densitometry values calculated for western blot analysis of 
phase I & II enzyme expression and related xenobiotic sensing nuclear 




















AhR 58410 29526 -2 17585 -2 14032 -2 
AhRR 53603 13357 -4 27057 2 21555 2 
ARNT 1 58885 40294 -1 34663 -1 15608 -3 
CYP1A1 2726 9826 4 8187 -1 4482 -2 
CYP1B1 3384 9273 3 9723 1 6887 -1 
Nrf2 37037 59867 2 58756 -1 44028 -1 
VDR 27347 32973 1 50719 2 45036 1 
PXR 42009 69029 2 72372 1 60007 -1 
GSTM1 6380 5734 -1 11143 2 7378 1 













adjacent normal tissue, and EGFR (Y1068 and Y1173) in colon tumor tissue. 
However, no work had been conducted to assess whether Anthos modulated 
phase I and II enzyme expression in colon or liver tissue in animals treated with 
ETBF bacteria. Results from our survey of the impact of Anthos and ExoAnthos 
on key phase I and II enzymes involved in the metabolism of the environmental 
carcinogen B[a]P as well as other carcinogens, demonstrated significant 
modulation of the phase I enzymes CYP1A1 and CYP1B1 and phase II enzymes 
GSTM1 and SULT1 by Anthos and ExoAnthos  (Figures 17-18) in normal colon 
tissue. Our survey of nuclear transcription factors and associated proteins 
including AhR, AhRR, ARNT1, Nrf2, VDR and PXR  found that Anthos led to 
increases in the expression of the AhR repressor AhRR when compared to ETBF 
alone treated animals. Interestingly, ExoAnthos treatment was not shown to 
increase expression of AhRR but rather it led to decreased expression of the aryl 
hydrocarbon receptor nuclear translocator, ARNT1. No significant changes were 
noted in the expression of PXR, Nrf2, or VDR in colon samples from Anthos or 
ExoAnthos treated animals. Results from the enzyme expression analysis of liver 
tissues taken from the same animals noted similar decreases in the expression 
of CYP1A1 in Anthos treated mice and increases in the phase II enzymes 
GSTM1 and UGT1A6 (Figures 19-20). No significant changes in expression of 
mEH or SULT1 were noted in liver tissue. A significant decrease in AhR was 
noted in ExoAnthos treated mice and a significant increase in AhRR expression 

















Figure 19. In vivo changes in phase I and II enzyme expression and related 
xenobiotic sensing nuclear receptors in liver tissue following treatment 
with ETBF bacteria, bilberry-derived Anthos or ExoAnthos: changes in the 
expression of key phase I and II enzymes along with key nuclear receptors 
including CYP1A1, mEH, GSTM1, SULT1, AhR, AhRR, in liver tissue  taken from 
ETBF-inoculated ApcMin/+  mice after treatment with bilberry-derived Anthos, 
ExoAnthos or vehicle control. Assessed using western blot analysis compared to 










Figure 20. Representative heatmaps for In vivo changes in phase I & II 
enzyme expression and related xenobiotic sensing nuclear receptors in 
liver tissue: heatmaps and significance levels produced from western blot data 
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 P < 0.01 ** 
    P < 0.001 *** 
       Fold change in expression 
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Table 4. Raw densitometry values calculated for western blot analysis of 
phase I & II enzyme expression and related xenobiotic sensing nuclear 































AhR 943 34419 37 44576 1 38634 1 6464 -7 
AhRR 51013 38000 -1 26864 -1 71099 2 42221 2 
CYP1A1 40740 30904 -1 20889 -1 9504 -3 9614 -2 
mEH 28247 30977 1 37739 1 30286 -1 36194 -1 
SULT1 37873 55699 1 46368 -1 46320 -1 32923 -1 
GSTM1 34244 11042 -3 29548 3 19038 2 26604 -1 
















Expression in tumor tissue 
Alterations of phase I and II enzymes have been attributed to being one of the 
causes for the development of chemo-resistance in cancer [162, 163]. Since 
modulation of phase I and II enzymes were demonstrated in normal colon and 
liver tissues, we sought to determine whether additional chemo-resistance could 
arise for individuals undergoing chemotherapy if they were taking Anthos. In 
order to do this, we assessed the expression of the phase II enzymes: GSTM1, 
SULT1, and UGT1A6 in the tumor tissue taken from Anthos treated vs. ETBF 
control mice. Results from this analysis (Figure 21) showed that Anthos 
treatment led to no significant changes in the expression of the phase II 
enzymes: UGT1A6, GSTM1, or SULT1 in the tumor tissue.  
Impact of Anthos treatment on alterations induced by B[a]P treatment in 
vitro 
Alterations in the expression of phase I enzymes had been previously reported 
by our laboratory in an ACI rat model for breast cancer [157].  Given this 
background, we next sought to determine if Anthos and ExoAnthos treatment 
would alter this shift in phase I/II enzyme expression induced by B[a]P treatment, 
in vitro. Results (Figure 22) showed that cells treated overnight with B[a]P (20 
µM) featured increased expression of CYP1A1 with decreased expression of 
GSTM1. Furthermore, treatment with Anthos led to significant decreases in the 
expression of CYP1A1 while significantly increasing the  phase II detoxifying 











Figure 21. Impact of in vivo Anthos treatment on phase II enzyme 
expression in colon tumor tissue: changes in the expression of key phase II 
enzymes including GSTM1 (P>0.2), SULT1 (P>0.2) and UGT1A6 (P>0.5) taken 
from ETBF-inoculated ApcMin/+  mice after treatment with bilberry-derived Anthos 




3-fold reductions in the expression of a key transcription factor AhR, which is 
involved in the expression of CYP1A1, in HCT-116 colon cancer cells. 
Furthermore, Anthos treatment simultaneously led to a nearly 2-fold increase in 
the expression of the AhR repressor, AhRR. Anthos treatment also led to 2- to 
greater than 10-fold increases in the expression of a key nuclear receptor, PXR, 
which regulates the detoxification process by upregulating enzymes UDPGT, 
GSTs and SULTs when it identifies the presence of foreign potentially toxic 
substrates [164]. It should be noted that the expression was enhanced, although 






















Figure 22.  Changes in expression of key phase I and II enzymes and 
related nuclear receptors following treatment with B[a]P versus B[a]P and 
Anthos. Colon cancer cell line HCT-116 was pre-treated with various 
concentrations of Anthos for 24 h followed by co-treatment with B[a]P and Anthos 
for 24 h and the effect on expression of AhR, AhRR, CYP1A1, SULT1, and 
GSTM1 was assessed using western blot analysis and compared to β-actin 
loading control. Densitometry values listed are the ratio of each dose to the 
vehicle control (a) and B[a]P control (b), corrected for β-actin loading control. 




Given the recent uptick in cases of CRC diagnosed in younger individuals [12], 
CRC appears to be making a comeback and thus warrants research into 
identifying potential chemopreventive methods to combat this disease. Although 
much research has been conducted on the role of carcinogens such as B[a]P on 
the development of colorectal cancer, little has been achieved in successful 
prevention of this disease in populations who are exposed to such environmental 
carcinogens on a daily basis. It should be noted that many studies have been 
conducted on a variety of plant-derived chemopreventive agents but few agents 
have successfully been translated, perhaps due to a generalized poor 
understanding of how they function mechanistically and issues pertaining to 
bioavailability. For instance, anthocyanins have been attributed with a variety of 
health-promoting benefits including chemopreventive and therapeutic effects due 
to their roles as anti-inflammatory and antioxidant agents [94, 131]. However, no 
studies investigating the impact of Anthos on the balance of phase I/II enzymes 
in the colon had been reported in the literature. Furthermore, the impact of 
bacteria such as ETBF on this balance in the colon and liver has also yet to be 
elucidated. Given the lack of understanding/knowledge in these areas, we sought 







Bacteria and role of ETBF in modulating phase I/II  enzymes 
Several recent studies have confirmed the link between dysbiosis of the gut 
microbiome and colorectal cancer. Several bacteria in particular have been 
associated with increased risk of developing CRC including: S. gallolyticus, H. 
pylori, virulent forms of Escherichia coli (E. coli), Fusobacterium nucleatum (F. 
nucleatum), Salmonella enterica (S. enterica) and enterotoxigenic B. fragilis 
[155]. Although much research has been conducted on the role of bacteria on 
inflammation and carcinogenesis  [28, 147, 165],not much has been uncovered 
on the role of ETBF on the expression of phase I and II enzymes. Results from 
our assessment of the impact that ETBF has on the expression of phase I and II 
enzymes in ApcMin/+ mice showed that treatment with the bacteria led to 
significant increases in the expression of the phase I enzymes CYP1A1 and 
CYP1B1 in normal colon tissue. Furthermore, highly significant increases in the 
expression of AhR and significant decreases in the expression of the phase II 
enzymes GSTM1 and UGT1A6 were noted in liver tissue samples taken from 
ETBF mice when compared to mice that did not receive the bacteria. The results 
gathered in this study provide an additional link between how “bad” bacteria such 
as ETBF can ultimately lead to the development of cancer beyond the initially 






 Exo Anthos, Anthos modulate expression of phase I/II enzymes in normal 
but not colon tumor tissue  
After elucidating how ETBF bacteria increases the expression of phase I 
enzymes while decreasing the expression of the phase II enzymes in normal 
colon and liver tissue, we next wanted to determine if Anthos or ExoAnthos 
treatment could alter this enzyme imbalance. We have previously reported that 
Anthos treatment led to reductions in the phosphorylation status of Src, EGFR, 
STAT3, STAT5 and expression of COX-2, Cyclin D1 and Cyclin D2 in this animal 
model (Chapter 2). Furthermore, previous work from our laboratory has shown 
that Anthos treatment led to decreased expression and activity of CYP1A1 and 
CYP1A2 in a breast cancer model [157]. Results from this series of studies 
showed that Anthos and ExoAnthos treatment significantly decreased the 
expression of phase I enzymes CYP1A1 and CYP1B1, while increasing the 
expression of the phase II enzymes GSTM1 and SULT1. Our survey of AhR, 
ARNT1 and AhRR expression suggest that the modulation of phase I and II 
enzymes could be attributable to the altered expression of AhRR and ARNT1 
induced by Anthos and ExoAnthos treatment. It should be noted that AhRR is a 
key protein in the AhR signaling cascade that acts as a repressor of AhR-
dependent gene expression. Structural work shows that AhRR acts by 
competitively repressing AhR binding to ARNT and target DNA [166] . 
Furthermore, AhRR levels have been shown to decline in a variety of disease 
states ranging from rheumatoid arthritis [167] to lung cancer [168]. Interestingly, 
DNA methylation at AHRR has also been shown to be a marker for smoking and 
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was correlated with future smoking morbidity and mortality [169] .  As noted 
above, ARNT1 is also a key component of the AhR signaling cascade and 
functions by binding to the ligand bound form of AhR and aiding in the movement 
of the AhR complex to the nucleus. ARNT has also been shown to be 
upregulated under hypoxic conditions by a HIF-1α dependent mechanism in 
Hep3B cells [170].  
Importantly, no significant changes in the expression of the phase II enzymes 
UGT1A6, SULT1 or GSTM1 were noted in colon tumor tissue taken from animals 
treated with Anthos. Therefore, potential negative effects due to increased 
breakdown of chemotherapeutic drugs that may result from increased phase II 
enzyme expression, as evolves in many tumors, should not be a cause for 
concern with Anthos treatment. With this in mind, the selective increase in phase 
II enzyme expression in normal tissue over tumor tissue may actually be an 
advantage in decreasing off target toxicity to healthy tissue for drugs such as 
irinotecan [171]. However, additional studies would be needed to confirm this 
hypothesis. 
 
Influence of B[a]P and Anthos treatment on phase I and II enzyme 
expression 
Exposure to environmental pollutants is now considered to be one of the reasons 
behind the increasing rates of individuals with disorders ranging from obesity and 
type 2 diabetes to cancer [151, 153]. Up to 90% of CRC cases are of sporadic 
origin and it is estimated that diet contributes to 80% of known cases of CRC. 
99 
 
The role of chemicals that contaminate food and ultimately contribute to the 
development of CRC has been of great interest [153]. A class of compounds that 
is particularly relevant is PAHs. The PAH, B[a]P is of special interest due to its 
presence in a variety of common sources of exposure ranging from charcoal 
cooked food to cigarette smoke and several environmental sources and its 
epidemiological correlation with increased risk of CRC.  Similar to the alterations 
in phase I and II metabolism found to exist in vivo following ETBF inoculation, we 
found that cells treated overnight with B[a]P (20 µM) featured increased 
expression of the phase I enzyme CYP1A1 with decreased expression of the 
phase II enzyme GSTM1 as well as the AhR repressor, AhRR. These results 
suggest that dysbiosis of the gut microbiome and exposure to the environmental 
carcinogen B[a]P both lead to dysfunction of the balance between phase I and II 
enzymes in colon tissue. Furthermore, treatment with Anthos effectively shifted 
this balance in expression levels of AhRR, AhR, PXR, CYP1A1, and SULT1 to 
greater favor a state of detoxification in B[a]P treated cells. It should be noted 
that the beneficial effects attributed to consumption of Anthos in this study may 
vary from person to person depending upon the presence of genetic 
polymorphisms of these enzymes. However, since the expression of several 
enzymes were shown to be modulated by these compounds, individuals may still 
benefit overall by way of alternative enzymes. 
Overarching results from this study stress the importance of integrating the gut 
microbiome into the study of carcinogen metabolism and carcinogenesis. With 
the ever omnipresent threat and buildup of carcinogens within the industrialized 
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environment and the resulting inevitable daily exposure of the colon to these 
compounds, a more integrated approach to the prevention of cancer is needed. 
Future studies assessing potential synergy that may arise when dysbiosis of the 
gut microbiome is combined with exposure to environmental carcinogens such as 
B[a]P could lead to a better understanding and a potential explanation for the 
current upward tick in colorectal cancer cases. 
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MODULATION OF COLON INFLAMMATORY ENVIRONMENT BY BILBERRY-DERIVED 
ANTHOCYANIDINS 
Introduction 
A recent report on the incidence of colorectal cancer (CRC) has uncovered an 
alarming increase in the rate in individuals under the age of 40. Interestingly, this 
increase was only observed for cases in the  distal colon and rectum, which had 
previously been declining [12]. Although the cause for this shift has yet to be 
identified, one particularly compelling presumption would be to link an updated 
version of Strachan’s hygiene hypothesis [172]. This hypothesis associates the 
rise in atopic diseases such as food allergies, asthma, anaphylaxis, allergic 
rhinitis and atopic dermatitis and disorders of the immune system e.g.,   
inflammatory bowel disease (IBD) and type 1 diabetes (T1D) in the younger 
generations to the increase in “hygienic” environments in the “developed” world 
since the 1980’s. During this time, great strides have been made in the fight 
against infectious diseases due to increased vaccination rates, use of antibiotics 
and sanitation practices [173]. However, although the hygiene hypothesis makes 
a compelling case, additional changes such as alterations in diet, environmental 
carcinogens, exposure to parasites, increase in caesarean sections etc. have 
occurred concurrently during this time period. The updated hypothesis which now 
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targets promoting a healthy microbiome while maintaining stringent  standards 
for avoiding infectious diseases has taken on a variety of names such as 
microbiome depletion hypothesis, old friends hypothesis, microbial diversity 
hypothesis and targeted hygiene hypothesis [174].  
Bacteria and evasion of immune response 
Traditionally, the cause for the development of CRC has been attributed to the 
presence of genetic mutations. However, the role of the gut microbiome in the 
development of cancer, with a special emphasis on CRC, has been gaining ever-
increasing traction within the scientific community over the past 10 years. 
Specifically, findings link the dysbiosis of the gut microbiome and the resulting 
inflammation to genotoxicity and ultimately carcinogenesis. Various mechanisms 
by which these “bad” bacteria take root and evade the immune system have 
been hypothesized and include the ability of toxin-producing bacteria such as H. 
pylori and B. fragilis to evade the normal host response. This was found to be in 
part due to their ability to elicite a Th2 over Th1 response caused by their lipid A 
structural differences which fail to activate toll like receptor 4 (TLR4), but activate 
toll like receptor 2 (TLR2) [175]. Originally described by Mosmann et al., the T 
helper (Th) cell balance between Th1 and Th2 cell subtypes, Th2 dominated 
imbalances, which lead to increases in IL-4, IL-5 and IL-13, were found to lead to 
allergen sensitization. In contrast, imbalances favoring Th1 type responses, 
which lead to increases in IFN-γ, were shown to suppress Th2 and ultimately 
lead to the inhibition of atopic immunopathology.  
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A more recently identified Th subtype is Th17. Under normal functioning 
conditions, Th17 cells aid in defending the host against extracellular pathogens. 
This is accomplished by aiding in the recruitment of macrophages and 
neutrophils to the infected tissue. However, when dysregulated Th17 cells can 
lead to chronic inflammatory diseases such as multiple sclerosis, rheumatoid 
arthritis, psoriasis, asthma and inflammatory bowel disease [176]. Recent studies 
have linked the environmental factors such as diet and intestinal microbiota to 
this dysregulation of cytokine regulation ultimately spurring autoimmunity and 
disease [177].  Interestingly, studies have linked diets high in trans fatty acids 
with increased expression of IL-17 and RORγt expression which are 
characteristic of a Th17 response and intestinal inflammation in DSS treated 
mice [178]. Additionally, a diet high in salt was linked with promotion of both Th17 
differentiation and the induction of autoimmunity [179].  
One particular strain of bacteria that has gained attention for both its relevance in 
clinical populations for CRC, FAP and diarrheal disease is Enterotoxigenic 
Bacteriodes fragilis (ETBF). ETBF bacteria are a subset of B. fragilis bacteria that 
secrete the metalloprotease toxin, B. fragilis toxin (BFT). This 20 kDa zinc-
dependent metalloprotease leads to the cleavage of E-cadherin thus increasing 
permeability and exposing the submucosa of the colon to bacterial antigens from 
the lumen.  Additionally, the tumorigenesis induced by ETBF bacteria has been 
found to be driven by Th17 response and increased STAT3 activity.  
Like many biological processes, the balance between these competing pathways 
is crucial in maintaining an optimal disease-free state. Excess of any one of 
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these pathways under certain conditions can lead to a variety of diseases such 
as asthma, rheumatoid arthritis, colitis, and cancer [180, 181].  It has also been 
shown that by depleting the Tregs in ETBF-colonized C57BL/6 FOXP3(DTR) 
mice, there was an effective shift toward enhanced colitis, but reduced 
tumorigenesis. This was attributed to the shift in the  mucosal cytokine profile 
from  IL17 to IFNγ [182]. A variety of factors have been found to influence Th17 
cell differentiation. These factors include but are not limited to the following: 
influence of Treg, PD-L1, AhR, COX-2/PGE2 [183]. 
Programmed death-ligand 1 (PD-L1) 
A number of promising immunotherapeutic treatments such as ipilimumab (anti-
CTLA-4 therapy), pembrolizumab (anti-PD-1 therapy), nivolumab (anti-PD-1 
therapy), atezolizumab (anti-PD-L1 therapy), avelumab (anti-PD-L1 therapy), and 
durvalumab (anti-PD-L1 therapy) have recently been developed and successfully 
applied to the treatment of several different types of cancer such as melanoma, 
Hodgkin lymphoma, urothelial carcinoma and non-small cell lung cancer. Of 
these immune therapies, one of the most common targets is the programmed 
death ligand 1 (PD-L1) and its receptor programmed death 1 (PD-1) receptor. 
The PD-1 receptor is expressed by T lymphocytes, B, natural killer T, and Treg 
cells, where it functions as an inhibitory receptor which effectively diminishes the 
immune response via down-regulation and promotes self-tolerance by 
suppressing T cell inflammatory activity. Under normal functioning conditions this 
helps prevent autoimmune disease. However, this mechanism is often redirected 
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by cancer cells, which highly express the PD-1 ligand, PD-L1, in order to prevent 
the immune system recognition and attack.  
With the recent rise in use of the checkpoint inhibitors such as anti-PD1 and anti-
CTLA-4 therapies, side effects classified as immune-related adverse events 
(irAEs) ranging from pneumonitis and hepatitis to colitis have arisen [184]. More 
specifically, it has been found that a new inflammatory bowel disease phenotype 
that shares traits with both ulcerative colitis (UC) and crohn’s disease (CD) can 
occur with use of these therapies [184]. These side effects are not surprising 
considering that several studies have shown that polymorphisms in these 
proteins are associated with autoimmune diseases such as type 1 diabetes 
mellitus (T1DM), systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA) [185]. Interestingly, upregulation of PD-L1 has been found to restrain Th17 
cell differentiation [186]. As noted  previously, Th17 is one of the main drivers by 
which ETBF bacteria drives inflammation-induced colon carcinogenesis [138]. 
Therefore, although PD-L1 has a deleterious role when expressed in the tumor 
microenvironment, a more careful consideration of the endogenous role of PD-L1 
in normal colon tissue must be addressed. 
Role of COX-2 in PD-L1 expression and Th17 differentiation 
Even though COX-2 was originally identified in 1989 by Needleman and 
coworkers, COX-2 and COX-1 have been anti-inflammatory targets from the 
ancient time - since  1500 BC [187]. COX-2 is typically expressed only under 
conditions where prostaglandins are upregulated which occurs during 
inflammation and have thus been a key target for research relating to the 
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treatment and prevention of diseases such as rheumatoid arthritis, osteoarthritis, 
and cancers of the prostate, breast, lung and colon [188]. In addition to the more 
traditional therapeutic applications of the COX-2/PGE2 pathway, recent research 
has highlighted the influence of more mechanistic role of this pathway on PD-L1 
expression and Th17 development. For instance, it has also been shown that 
tumor cells can induce PD-L1 expression in macrophages and myeloid-derived 
suppressor cells by altering PGE2 metabolism in hematopoietic cells and that 
COX-2 inhibition could help to regulate these changes in PD-L1 expression [189]. 
Furthermore, COX-2 expression was also found to be positively correlated with 
PD-L1 expression in melanoma and inhibition of COX-2 by celecoxib effectively 
down-regulated PD-L1 expression in two melanoma cell lines [190]. Interestingly, 
COX-2 expression was found to increase expression of IL-4 and IDO but was 
also found to be inversely related to expression of IFN-γ in fibrosarcomas [191]. 
Thus, under circumstances of high local expression of COX-2 it is thought that 
this induces immunosuppression and ultimately impairs the T cell effector 
functions which are mediated by IFN-γ [191]. 
In addition to influencing PD-L1 expression, the PGE2/COX2  pathway has also 
been found to influence Th17 differentiation. PGE2 has been shown to promote 
the differentiation and pro-inflammatory functioning of Th17 cells in both mice 
and humans by inducing EP2 and EP4 signaling altering  IFN-γ, and IL-10  
production [192]. PGE2 was also found to be required for IL-17 production in the 
presence of APC cells [192]. With the ever-expanding mechanistic influence of 
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this pathway, it appears that the “gold-standard” for inflammation and the 
prevention thereof still has a few mysteries that have yet to be unraveled. 
With the above factors in mind, it is easy for one to grasp how complex the 
balance in host immune response can be. Given the deleterious role of Th17 in 
carcinogenesis induced by ETBF bacteria residing in the colon, identifying a 
method by which this imbalance in T helper cell signaling can be restored in 
order for the host to identify and effectively rid itself of ETBF, while limiting harm 
to itself, would be an ideal scenario.  
 
Modulation of gut microbiome dialogue with host 
An important factor that should be considered when addressing dysbiosis of the 
gut microbiome is the role that factors ranging from diet, whether an individual 
was breast fed [193], antibiotic usage or whether they were exposed to 
environmental carcinogens should be considered regarding the formation of 
dysbiosis. For instance, the influence of dietary intake  of refined sugars has 
been found to increase levels of C. difficile and C. perringens  which has been 
linked to IBD[194]. Furthermore, individuals who consumed a more plant-based 
agrarian diet versus Western-style diet rich in meat and fat were found to have 
altered microbiomes [195, 196]. With the influence of dietary intake in mind, the 
potential role of particular phytochemicals on the gut microbiome and its 
interaction with the host is a key factor that needs to be investigated. 
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Anthocyanin-rich foods have been a dietary staple seemingly since the dawn of 
time. Known for their characteristically-rich purple, blue and red hues that 
canvas/envelop a variety of fruits, vegetables, grains and flowers, anthocyanins 
have been attributed to providing a variety of health promoting properties  such 
as activities including anti-inflammatory [94], chemopreventive and 
chemotherapeutic [86, 130], obesity control, cardiovascular disease prevention, 
and alleviation of the symptoms of diabetes [131].   
As work presented in the preceding chapters has shown,  Anthos works on a 
variety of pathways including, phosphorylation status of Src and EGFR and 
modulation of phase I/II enzyme expression in and ETBF bacterially-driven model 
of CRC in ApcMin/+ mice. For this series of studies, we turned our attention to the 
influence of Anthos on the inflammatory response to ETBF bacteria both within 
the tumor and adjacent normal microenvironments and the influence of Anthos 
dose on colon tumor number and tumor grade.   
Methods 
Anthos Isolation and Purity  
The native bilberry Anthos mixture that was generously provided by 3P 
Biotechnologies (Louisville, KY) was further enriched using C18 Sep-Pak 
cartridges (Waters, Milford, MA) and eluted in acidified (0.1% HCl) ethanol. The 
enriched extract was then dried using a Savant SC210A Speed-Vac 
(ThermoFisher Scientific, Waltham, MA) and stored at -20 °C, under argon. 
Purity was determined  by HPLC-PDA-UV. Briefly, 15 µl samples were analyzed 
using a Shimadzu Premier C18 reverse-phase column (250x4.6 mm i.d., 5 µm). 
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Mobile phase A was composed of water: formic acid: acetonitrile (87:10:3) and 
mobile phase B was composed of water: formic acid: acetonitrile (40:10:50). The 
flow rate was 0.6 ml/min and the gradient condition was 0-5 min 5% B; 5-15 min 
15% B; 15-20 min 25% B; 20-30 min 35% B; 30-40 min 45% B; 40-45 min 100% 
B; 45-50 min 5% B. Detection of Anthos was at 520 nm by PDA-UV and total 
Anthos concentration was calculated using a standard curve. The reference 
anthocyanidins  were purchased from Cayman Chemical Company (Ann Arbor, 
MI). 
In vivo Anthos dose escalation study 
Animal experiments were performed in agreement with an approved protocol by 
the Institutional Animal Care and Use Committee at the University of Louisville. 
Breeding colonies were established in collaboration with  Dr. Nejat K. Egilmez’s 
lab [138] at the University of Louisville using C57BL/6J Min/+ (ApcMin/+) mice that 
were originally attained from Jackson Laboratories (Bar Harbour, ME). Mice were 
genotyped for the APC mutation using PCR according to the protocol established 
by Jackson Laboratories. Mice were fed a standard chow diet and received water 
ad libitum and were maintained on a standard light/dark cycle for the duration of 
the study. At 5-6 weeks of age, animals were administered antibiotic. Four days 
later the animals were administered ETBF to promote tumorigenesis and one 
week following ETBF inoculation, animals began their respective treatment 
regimen. The dose escalation study featured three doses, namely, low (8.6 
mg/kg/day, i.e. 60 mg/kg/wk), medium (17.1 mg/kg/day, i.e. 120 mg/kg/wk) and 
high (34.3 mg/kg/day, i.e. 240 mg/kg/wk) dosages. Male and female ApcMin/+ 
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mice (n=5 combined) were randomly assigned to each treatment or vehicle 
control group and were treated via oral gavage three times per week for 4 weeks. 
Animals were culled in the fed state at 12 weeks, colon tumors were counted and 
tissues were harvested.  
 
Pathology  
Following excision, colon tumor and mesenteric lymph tissue were immediately 
fixed in a solution of 10% formalin. After 48 hours, samples were transferred to a 
solution of 70% ethanol. Samples were embedded in paraffin and sectioned by 
the pathology core research laboratory, department of pathology and laboratory 
medicine at the University of Louisville. Slides were embedded in paraffin, 
sectioned and stained with H&E and subsequently evaluated by pathologist, Dr. 
Mostafa Fraig. Digital slides were captured using a Leica Aperio digital pathology 
slide scanner (Leica Biosystems, Wetzlar, Germany). 
Western-blot analysis  
For western-blot analysis, 40 µg of protein from in vitro and in vivo tissue lysates 
was by 4 – 12 % polyacrylamimide - SDS  gel electrophoresis and 
electrotransferred to polyvinylidene difluoride membranes by semi-dry transfer 
(Biorad Trans-blot SD, Hercules, CA). Blots were blocked with 4% dry powder 
milk or BSA for 1 h and then incubated with primary antibodies p21, IFN-γ, TLR-
4, phosphor-p38, phosphoVEGF, IFN-β, VEGF and COX-2 which were all 
acquired  from Santa Cruz Biotech (Santa Cruz, CA) and PD-L1 which was 
acquired from Proteintech (Rosemont, IL) at 4ºC overnight and secondary 
antibodies (Santa Cruz Biotech, Santa Cruz, CA). conjugated to peroxidase for 1 
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h at room temperature. Blots were then developed with an ECL detection system. 




Effect of Anthos on tumor inhibition 
Following our previous findings, we pursued a detailed dose-escalation study  to 
determine the influence of Anthos dosage on tumor count. Three doses were 
tested - low (8.6 mg/kg/day, i.e. 60 mg/kg/wk), medium (17.1 mg/kg/day, i.e. 120 
mg/kg/wk) and high (34.3 mg/kg/day, i.e. 240 mg/kg/wk). Controls included a 
vehicle control and an ApcMin/+ mice without ETBF bacteria control. Results from 
this study (Figure 23) showed a clear significant dose- dependent decrease in 
colon tumor counts in Anthos-treated groups. Significant differences in tumor 
counts were noted between control and low dose animals (P=0.003), control and 
medium dose animals (P=0.0004), control and high dose animals (P<0.0001). 
Additionally, significant inter-treatment group differences were noted for medium 
and high doses (P=0.0001) and low and high doses (P<0.0001). The difference 
between low and medium treatment groups was not statistically significant 
(P=0.054). No significant difference in tumor number was noted between male 












Figure 23.  In vivo Anthos dose escalation study: ApcMin/+ mice inoculated 
with ETBF were treated via oral gavage, three doses a week for 4 weeks with low 
(8.6 mg/kg), medium (17.1 mg/kg) and high (34.3 mg/kg) dosages or vehicle 
control. (A) Study overview. (B) tumor numbers. Black triangles represent males 
and black circles represent females. *** signifies P<0.001, ** signifies P<0.01, 
and * signifies P<0.05. 
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Control Low Medium High 
1 F 20 9 10 4 
2 F 25 12 12 3 
3 F 24 15 10 2 
4 F 15 14 11 1 
5 M 23 12 7 5 
















Figure 24. Anthos-treated ApcMin/+ mice inoculated with ETBF featured 
fewer, more well differentiated tumors, with immune response:  
Representative photographs of histological analysis of colon adjacent normal and 
tumor samples taken from  Anthos-treated  (4E, 4F) and  vehicle control (4C, 4D) 
as compared to normal colon tissue (4A, 4B). Paraffin sections of colons were 
stained with H&E. Arrows in 4C and 4D highlight representative tumors (4C) and 
necrotic patches (4D) observed in vehicle control mice. Arrows in 4E and 4F 
represent lymphoid aggregates adjacent to normal (4E) and tumor and normal 
colon tissue (4F). No lymphoid aggregates were observed in vehicle control 




In vivo look at inflammation 
Building upon the findings regarding the influence of Anthos on the 
phosphorylation status of Src and EGFR, STAT3, STAT5 and downstream 
expression of key targets cyclin D1 and cyclin D2 that were presented in the 
previous chapter, we next sought to determine the influence of Anthos treatment 
on the inflammatory tumor and adjacent normal microenvironments in the same 
ETBF ApcMin/+ mouse model. Results from our western blot analysis (Figures 25-
27) of the inflammation pathways associated with CRC and immune checkpoint 
function showed significant increases in the expression of IFN-γ (P=0.04), 
phospho-p38 (P=0.03), and levels of TLR-4 (P=0.01), and significant decreases 
in the expression of COX-2 (P=0.001), in adjacent normal tissue. In the tumor 
tissue microenvironment, decreased levels of TLR-4 (P=0.01) were noted along 
with decreased expression of COX-2 (P=0.03), and increased expression of p21 
(P=0.03) in Anthos vehicle control animals. Interestingly, expression of the key 
immune checkpoint protein, PD-L1, was significantly increased in adjacent 
normal tissue (P=0.01) of animals treated with Anthos versus vehicle control and 
significantly decreased in tumor tissue in these same Anthos versus control 





Figure 25. In vivo changes in PD-L1 related expression and upstream 
pathways following treatment with Anthos: changes in the phosphorylation 
and expression of EGFR along with corresponding downstream pathway targets 
including STAT3, PD-L1, COX-2 and IFN-γ related pathways in a) adjacent 
normal  and b) tumor colon tissue taken from ETBF-inoculated ApcMin/+  mice 
after treatment with Anthos or vehicle control as assessed using western blot 


































Figure 26. Representative heatmap for in vivo changes in PD-L1 related 
expression and upstream pathways following treatment with Anthos:  
representative heat map legend depicts the average fold change and significance 
level in either phosphorylation status or expression levels between Anthos 
treated and vehicle control animals within either adjacent normal (n=3) or tumor 











































Significance level attained 
for comparison of average 
Anthos to control sample 
expression/phosphorylation 
P < 0.05 *
P < 0.01 **




Table 6. Raw densitometry values calculated for PD-L1/inflammation 
pathway western blot analysis: values determined using ImageJ software  
Target 







EGFR 18661 20531 1 18388 20599 1 
pEGFR 
(Y1068) 
19771 17469 -1 25990 12493 -2 
pSTAT3 15938 11067 -1 25354 5274 -5 
STAT3 5088 7000 1 10291 8208 -1 
COX-2 19808 2687 -7 18224 4358 -4 
TLR-4 3739 10338 3 10756 7058 -2 
p-p38 3069 7907 3 9136 5246 -2 
IFN-β 6487 5833 -1 10840 9090 -1 
IFN-γ 2898 5816 2 9955 11484 1 






Figure 27. Tentative pathways for modulation of PD-L1 expression: outline 
of EGFR and IFN-γ driven expression of PD-L1 proposed for adjacent normal 
and tumor tissue samples. Pathway is a modified version of the Qiagen EGFR 









Figure 28. In vitro changes in PD-L1 expression and related EGFR 
phosphorylation status following Bilberry-derived Anthos and 
anthocyanidin treatment: a) dose dependent changes in the phosphorylation 
status of EGFR (Y1068) and downstream PD-L1 expression in HT-29 cells 
treated with varying concentrations of bilberry-derived Anthos; b) influence of 
indicated individual anthocyanidins (100 µM) on PD-L1 expression in HT-29 
colon cancer cells as assessed using western blot analysis with β-actin and 
GAPDH loading controls. 
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In vitro impact of Anthos and individual anthocyanidins on PD-L1 
expression 
Following the promising findings in vivo, we wanted to confirm that Anthos 
treatment decreased PD-L1 expression in vitro in established human colon 
cancer cell lines, HT-29 and HCT-116. Results from our look at PD-L1 
expression in these two colon cancer cell lines showed that Anthos treatment led 
to dose-dependent decreases in PD-L1 expression (Figure 28). Follow-up work 
assessing the influence of each individual anthocyanidin and comparing it to the 
native Anthos mixture showed that the most impressive reduction in PD-L1 
expression was achieved by petunidin (Figure 28) at the same dosage (100 µM). 
 
Discussion  
In the previous chapters (Chapters 2 and 3, we identified Anthos as a 
promising chemopreventive agent against colorectal tumor development in 
an ApcMin/+ ETBF mouse CRC model. We showed that Anthos functions by 
decreasing the phosphorylation of Src and EGFR thereby modulating 
phosphorylation status or expression of key downstream players including 
STAT3, STAT5, COX-2, Cyclin D1 and Cyclin D2 in chapter 2. We also showed 
that Anthos treatment led to modulation of the metabolic detoxification pathways 
in chapter 3. In this chapter we therefore sought to determine the influence of 
Anthos treatment on the inflammatory environment in colon adjacent normal and 
tumor tissue in an ApcMin/+ ETBF model. We also sought to identify the dose-




ETBF bacteria is the prototypical bacteria posited to serve as an “alpha-bug” 
which is both directly pro-oncogenic and is also able to influence and remodel the 
colonic microbiome in such a way that ultimately further promotes its own ability 
to induce mucosal immune responses and changes within the colon epithelial 
cells ultimately resulting in colon cancer [24]. ETBF bacteria are a subclass of the 
B. fragilis bacteria that secrete the metalloprotease, B. fragilis toxin, which is 
structurally related to the tetanus and diphtheria toxins. Ultimately, BFT leads to 
the stimulation of E-cadherin cleavage thereby leading to increased colon 
permeability, inflammation and β-catenin nuclear signaling [26]. It has also 
been previously shown that Treg depletion leads to the mitigation of the Th17 
response to ETBF bacteria in favor of a Th1 response [182].  Results from this 
series of studies suggests that Anthos treatment leads to increased levels of 
TLR4 and secreted IFN-γ and decreased expression of COX-2 in adjacent 
normal colon tissue and increased expression of p21 and decreased levels of 
TLR-4 in colon tumor tissue. Interestingly, we also showed that PD-L1 
expression was significantly upregulated in normal colon tissue and significantly 
decreased in colon tumor tissue samples taken from Anthos treated animals. The 
findings presented in chapter 2, which show that Anthos alter the phosphorylation 
status of EGFR and Src as well as downstream STAT3 in colon tumor tissues 
taken from the ETBF treated ApcMin/+ mice support the decrease in PD-L1 
expression noted in the same colon tumor tissue.  This modulatory specificity, 
which in effect, differentially modulates PD-L1 levels in colon tumor over normal 
tissue provides an interesting application for Anthos treatment to not only the 
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prevention of offsite toxicities associated with the current standard of care, but 
also serve as a potential modulator of PD-L1 over-expression specific to colon 
tumor tissue. 
 
In the previous chapters we have shown that Anthos treatment at 120 mg/kg/wk 
led to significant reductions in the number of colon tumors when compared to 
vehicle control animals. In order to gain a better understanding of the influence of 
Anthos dosage on tumor number we conducted a dose escalation study with 
Anthos in ApcMin/+ mice treated with ETBF bacteria. Results from this study 
showed a significant dose dependent decrease in tumors for all treatment 
groups. Treatment at the highest dose of 240 mg/kg/wk led to over an 86% 
reduction in colon tumor development (P< 0.001). The appearance of tumors in 
all treatment groups were also much flatter and smaller in size than the tumors 
from vehicle control animals.  
  
The influence of Anthos on the inflammatory environment identified in 
this chapter highlights the potential influence of these factors under conditions of 
environmental carcinogen exposure. It has been shown that polycyclic aromatic 
hydrocarbon (PAH) exposure induces Th17 cell differentiation and IL-17 
secretion in T cells in an AhR dependent mechanism [197]. As presented in 
previous chapters, along with this chapter ETBF bacteria and benzo[a]pyrene 
(B[a]P) were shown to also lead to increased levels of AhR expression in 
vivo and in vitro, respectively. With this in mind, one could extend these findings 
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to posit that the recent increases in autoimmune diseases such as IBD and T1D 
could potentially be associated with dual environmental insults such as 
carcinogen exposure and microbiome dysbiosis.     
  
The effect of the combined insult of environmental carcinogens such as PAHs 
and microbiome dysbiosis is still essentially unknown. 
Given the increasing industrialization of our environment and exposure to 
carcinogens such as B[a]P, additional research assessing whether a synergistic 
carcinogenic dialogue exists between the ETBF bacteria and the ubiquitous 
environmental carcinogen, B[a]P, is a key area of future research that is 
needed.  Additionally, further investigation into the exact nature of Anthos 
upregulation of AhRR is needed. Classically, AhRR expression is upregulated 
by AhR. Previous studies have found that different AhR ligands differentially 
induce distinctly different, ligand specific AhR dependent gene products 
[198]. AhR has also recently been identified as a player in intestinal barrier 
function, homeostasis, and intestinal immune  cells [199].  Interestingly, it has 
also been shown that activation of AhR by a high affinity ligand during Th17 
development  led to significant increases in not only the proportion of T cells but 
also their production of cytokines [200]. This is particularly interesting considering 
our findings in chapter 3, which showed how Anthos treatment influences the 




Although it was not in the scope of this chapter, the influence of Anthos on the 
gut microbiome is the next area of investigation that needs to be addressed. 
Although our preliminary look at the influence of Anthos on the total ETBF 
bacteria population in vitro suggests that Anthos does not directly influence the 
total CFUs of the ETBF bacteria in the absence of a cellular/immunological 
environment (unpublished data). However, the results presented here suggest 
that Anthos most likely influences the immunological balance in the colon 
adjacent normal and tumor microenvironment and may therefore, by extension, 
influence the host immune response against this toxigenic bacteria. Future work 
assessing the microbiomes of Anthos and vehicle treated animals using fecal 
and mucosal biopsy samples should aid in elucidating the influence of Anthos 
treatment on gut microbiota. Additionally, kinetic studies assessing the 
modulation of T helper cell populations in adjacent normal and tumor tissue in 
relation to the microbiome composition over time would also be needed to 
determine how these immune and bacterial populations change as a function of 
time with Anthos treatment.  
 
Overall, the findings from our survey of inflammatory environment changes 
brought about by Anthos treatment in ApcMin/+ mice that received ETBF bacteria 
suggests that Anthos treatment may lead to positive chemopreventive 
modulation of the inflammatory environment under similar conditions thus 
reinforcing the benefits of berry-derived compounds on the treatment and 




CRC: colorectal cancer ,IBD: inflammatory bowel disease, Th: T helper cell, TLR: 
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petunidin, Mv: malvidin, Pe: peonidin, HPLC: high performance liquid 
chromatography, PDA: photodiode array detector, UV: ultraviolet, ETBF: 















SUMMARY AND FUTURE DIRECTIONS 
Overall goals and specific aims 
The overarching goal of my doctoral work was to determine how Anthos 
modulates the chemopreventive effects against bacteria- and carcinogen-
induced colorectal cancer (CRC). In order to accomplish this task, the specific 
aims were set forth for the project and are as follows: 
Aim 1: Determine anti-proliferative efficacy of optimal mixture of Anthos against 
colon cancer cells in vitro.  
 Aim 2: Determine efficacy of Anthos against colorectal cancer using a bacteria-
driven ApcMin/+ ETBF mouse model.  
 Aim 3: Determine the mechanistic influence of Anthos on ETBF and the 
environmental carcinogen, B[a]P in CRC. 
 
Major findings from this dissertation 
Although much work has been conducted on the use of plant bioactives as a 
means of preventing and treating CRC, major limitations in bioavailability, 
stability and ultimately dosage have prevented its translation to the clinic/patient 
population. Results from this work show that Anthos treatment leads to the 
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ultimate prevention of CRC via several mechanisms including modulation of the 
phosphorylation state of Src and EGFR and the downstream players in these 
pathways, modulation of the expression of phase I and detoxifying phase II 
enzymes and potential harnessing of the gut’s ability to protect itself from the 
invasion of cancer-causing ETBF bacteria/dysbiosis.  
Modulation of Src/EGFR 
Prior to this work, it had been shown that APC deficiency was associated with an 
increase in EGFR activity and c-Src expression in ApcMin/+ mouse adenomas and 
intestinal enterocytes [146]. Furthermore, In addition to increasing the secretion 
of chloride and permeability of intestinal epithelial cells, BFT also activates 
STAT3 and TH17 responses and leads to increased COX-2 [147]. Additionally, 
overexpression of COX-2 has been noted in colon tumor tissue and plays a role 
in the pathogenesis of FAP, ETBF and ultimately colon cancer [148, 149]. 
However, no work had been conducted to assess the impact of Anthos or 
anthocyanins on Src in any cancer model or Anthos on EGFR in a CRC model. 
Results from our look at EGFR, Src, STAT3 and STAT5 phosphorylation status 
and expression of downstream proteins Cyclin D1, Cyclin D2 and COX-2 showed 
a significant decrease in Src phosphorylation (Y418), EGFR phosphorylation 
(Y845) and the downstream mediator STAT5a/b (Y694 and Y699), both in 
adjacent normal and colon tumor tissue taken from ETBF treated ApcMin/+ mice 
that received Anthos treatment. Furthermore, phosphorylation status of EGFR at 
Y1068 and Y1173 along with the downstream mediator STAT3 (Y705) was 
shown to decrease in tumor tissue in Anthos treated mice. Key regulators of cell 
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cycle progression and inflammation, including Cyclin D1, Cyclin D2 and COX-2, 
were shown to be favorably modulated by Anthos, with the most dramatic 
reductions in expression observed in tumor tissue samples. These highly novel 
findings provide great insight into how Anthos treatment is leading to such 
significant decreases in colon tumor numbers in this model.  
Phase I/II enzyme balance 
The role of the gut microbiome in the development of CRC has gained attention 
recently. However, little was previously known about the role of bacteria in 
modulating the balance between phase I and phase II enzyme expression in the 
liver and colon. Results from this series of studies showed that the ETBF bacteria 
led to significantly decreased expression of the phase II enzymes UGT1A6 and 
GSTM1 in in the liver while increasing the expression of the phase I enzymes 
CYP1A1 and CYP1B1 in the colon. Anthos and ExoAnthos treatment was also 
shown to decrease expression of phase I enzymes while increasing phase II 
enzyme expression in the colon and liver compared to ETBF treated control 
animals. Additionally, modulation of key transcription factor and regulators 
including AhR and AhRR, were shown to be induced in ETBF treated animals. 
Furthermore, Anthos and ExoAnthos treatment appeared to lead to positive 
changes in AhR, AhRR, ARNT1, and VDR expression in ETBF treated animals. 
Importantly, no significant differences in expression were noted for phase II 
enzymes in colon tumor tissue taken from Anthos versus vehicle control animals 
thereby alleviating potential concerns over increased degradation/excretion of 
chemo therapeutic drugs. An interesting and highly novel use for this finding 
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would be to potentially use Anthos treatment as a way to prevent issues of offsite 
toxicity for chemotherapeutic drugs such as irinotecan, given the significant 
increases in phase II enzyme expression that were noted in normal colon tissue 
gathered from Anthos-treated animals.  
In addition to examining the impact of Anthos treatment on the balance of phase 
I/II enzyme expression using a bacterially driven ApcMin/+ colon cancer model, we 
also determined the influence of Anthos treatment on enzyme balance when cells 
are undergoing insult by the ubiquitous environmental carcinogen, B[a]P in vitro. 
Results from this series of studies showed that Anthos treatment led to a dose-
dependent decrease back to baseline in cells treated with the carcinogen. These 
results combined with the highly novel findings regarding the influence of the 
ETBF bacteria on the enzyme balance suggest that the combined insult by gut 
bacterial dysbiosis and environmental carcinogens such as B[a]P could provide 
the perfect toxic storm and ultimately lead to the development of CRC. 
Furthermore, Anthos treatment appeared to reverse these alterations both in vitro 
and in vivo shifting the equilibrium toward a detoxification state.  
Inflammation 
Given the significant role that inflammation plays in CRC, we sought to determine 
the influence of Anthos treatment on cytokine and immunoregulatory expression 
in colon adjacent normal and tumor tissue. Results from this work show novel 
and highly significant modulation of the immune checkpoint protein, PD-L1 by 
Anthos in vivo. Modulation of this key protein may be a result of Anthos role in 
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decreasing the phosphorylation status of Src and EGFR, which ultimately was 
shown to alter STAT3 phosphorylation status in in vivo colon tumor tissue, a key 
regulator of PD-L1 transcription. In vitro work with the human colon cancer cell 
line, HT-29, confirmed that Anthos treatment led to a dose-dependent decrease 
in phosphorylation of EGFR (Y1068) and expression of PD-L1.  Upregulation of 
PD-L1 in normal colon tissue may be induced by the increased IFN-γ expression 
that was noted in this tissue. Although a more intensive study of the immune 
regulatory environment is needed to more conclusively assess the true influence 
that Anthos has on the colon immune response, the survey presented here 
provides a highly intriguing look at how Anthos may be working in this bacterially-
driven model of CRC. This combined with the highly significant decreases in 
colon tumor numbers in Anthos treated animals further confirm this beneficial 
influence which may be of great use in the clinical setting as both a protective as 
well as therapeutic treatment.  
 
Influence of Anthos dose 
Given the intriguing results that we gathered from our initial in vivo Anthos and 
ExoAnthos studies, we carried out a dose-escalation study. The follow-up dose 
escalation study of Anthos in ApcMin/+ mice treated with ETBF bacteria showed 
that there was a clear dose-dependent decrease in the number of colon tumors 
in mice treated with varying doses of Anthos. At the highest dose of 240 
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mg/kg/week which equates to daily dose of about 34 mg/kg led to greater than 
86% reduction in the formation of colon adenomas.  
Although identifying all of the mechanisms by which Anthos work to modulate the 
development of CRC is beyond the scope of my project, the findings contained 
within this dissertation make important strides toward identifying the intricate and 
highly interdependent mechanisms by which this ultimate goal is achieved. From 
ancient times, plant-derived compounds such as anthocyanins have been key 
staples both within our diets and as medicinal remedies. Unfortunately, the multi-
faceted approach by which these compounds work is sometimes lost due to their 
seemingly mundane origins. With this in mind, the author of this dissertation 
hopes that one of the major messages that the reader will derive from this work is 
the strength and complexity that natural compounds such as Anthos exert 
against diseases such as CRC. Furthermore, the studies presented in this 
dissertation are merely the first step toward understanding how Anthos work, 
therefore, additional studies are indeed warranted, thus leading us to the final 
étape of this dissertation; future directions.  
Future Directions  
Future directions for this work would include conducting an in vivo experiment to 
assess the potential dialogue between B[a]P and dysbiosis of the gut microbiome 
induced by ETBF bacteria and how Anthos treatment may alter this hypothesized 
interaction. The results presented in this dissertation suggest that B[a]P and 
ETBF appear to shift the phase I/II enzyme equilibrium in a similar manner and 
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thus may have a detrimental  synergistic activity that could promote the formation 
of the active carcinogen BPDE. Additional work assessing the impact of Anthos 
treatment in non-transformed colon cells treated with B[a]P along with the 
formation of BPDE-DNA adducts would also be the logical next steps for this 
work. Ultimately, research into this area is made especially pressing given the 
recent rise in CRC in younger individuals.  
Additional in vitro work to assess the role of Anthos in modulating T helper cell 
balance would also be an important future project to undertake. Linking PD-L1 
and the known side effect of colitis with our findings in our in vivo ETBF ApcMin/+ 
mouse model treated with Anthos could be a key finding in overcoming the 
current limitations of this breakthrough immunotherapy treatment. The ultimate 
goal of this research is clinical translation of these findings. Therefore, 
conducting a clinical trial with these compounds is also planned by our laboratory 
for the future given the highly promising in vitro and in vivo results presented in 
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